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The first successful organ transplantation was a kidney transplantation between 
identical twins in Boston in 1954 1-3. Several years later, chemical immunosuppression 
with corticosteroids and azathioprine enabled transplantation between nonidentical 
individuals. Since 1966, kidney transplantations have also been performed in the 
Leiden University Medical Center (LUMC), the Netherlands. The introduction of new 
immunosuppressive agents and improvements in surgical techniques and post-trans-
plant care made organ transplantation a routine and preferred therapy for treatment 
of end-stage renal, cardiac, hepatic and pulmonary failure 3 and pancreatic transplan-
tation provides similar benefits for diabetic patients 4.
 Currently, there are believed to be more than one million individuals worldwide 
with an organ allograft 5, and this number will further increase. However, the success 
is complicated by several problems, including the discrepancy between the demand 
for and the supply of organs and the need for continuous immunosuppressive 
medication. In the Netherlands, roughly 1200 patients are on the waiting list for organ 
transplantation and the mean time to kidney transplantation is approximately 
4 years (figure 1). Complications from graft-preserving immunosuppression include 
an increased risk of malignancies 6, and of fungal, viral and parasitic infections 7, 8. 
This chapter will provide a background of current knowledge of post-transplant 
cancer, with a focus on skin cancer. Furthermore, the increased incidence of other skin 
diseases in organ transplant recipients (OTR) will be discussed.
Incidence of cancer in organ transplant recipients
In the first 4000 patients undergoing kidney transplantation, over 40 primary 
malignant neoplasms were reported 6. The increased risk of malignancies in OTR has 
been consistently supported by subsequent studies 9-13. The overall risk for any cancer 
can be estimated to be 2- to 5-fold greater in OTR than in the general population 13-17. 
This increased incidence has been shown to predominantly result from the occurrence 
of 4 distinct tumor types, namely non-melanocytic skin cancer (NMSC), lymphoprolif-
erative disorders, anogenital dysplasias and Kaposi’s sarcoma 9, 14, 16-19. Recent data have 
indicated that thyroid cancers can be added to the group of more frequent cancers 
following organ transplantation 20. Smaller, but significant, increases in hepatocellular 
and kidney cancers and some sarcomas have been observed 9, 14-17, 19. For many 




Figure 1   Kidney transplantations in the Netherlands
The number of patients on the waiting list for a kidney transplantation on the 31st December per year 
is presented in blue. The number of patients receiving a living, 
non-heart beating or heart-beating kidney transplantation per year in the Netherlands are presented 
by bars. Source of information: www.transplantatiestichting.nl 
jaarverslag 2008
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Transplantations living donors 
Transplantations non-heart-beating donors 
Transplantations heart-beating donors 
Postmortal donors eectuated 
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to be marginally or not significantly increased 12-14, 21. Other studies have even shown a 
slightly reduced incidence of breast 22, 23 and prostate carcinoma 22.
Skin cancer
The incidence of malignant melanoma has been shown to be 3-fold elevated in OTR 
compared with the general population 22, 24. Although low in absolute terms, the incidence 
of Kaposi’s sarcoma represented a 200-fold higher risk 17. The incidence of NMSC, including 
squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), has reported to be roughly 
55 times elevated 14, 25-28. As this increased NMSC risk results in excessive number of patients 
with NMSC, we will focus on the development of NMSC in OTR.
 NMSC is a collective term for SCC and BCC. SCC arise from malignant proliferation 
of the keratinocytes of the epidermis. The common clinical presentation of SCC is an 
erythematous keratotic papule or nodule that arises within a background of 
sun-damaged skin (Figure 2a). Lesions may ulcerate and have metastatic potential in 
around 5% 29. BCC arise from the basal layer of epidermis. No universally accepted 
classification exists for BCC, but the most common variant, accounting for 
approximately 60% of all primary BCC presents as a raised, translucent papule or 
nodule with telangiectasias (Figure 2b). As the lesions enlarge ulceration may occur, 
but usually BCC do not metastasize 29.
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Figure 2   Representative images of skin cancer A) Patient with a squamous cell 
carcinoma of the ear. B) Patient with a basal cell carcinoma on the cheek.
14
 The first report of increased NMSC in OTR came from Australia in the early 1970s, 
reporting seven patients with NMSC in a group of 51 kidney transplant recipients 
(KTR), which were immunosuppressed for up to 6 years 30. Other studies from highly 
sun exposed areas in the USA and Australia followed 31-36, suggesting that sun exposure 
is an important risk factor for the development of NMSC. In OTR a predominance of 
SCC over BCC was shown 31-36, while in the general population BCC are more common 
than SCC. When reports of skin cancer in OTR in more temperate climates, such as 
Scandinavia, the Netherlands, Britain and Ireland, showed increased incidences of 
NMSC as well 9, 35, 37-43, it became more evident that limited sun exposure combined 
with immunosuppression can also result in the development of NMSC. A progressive 
increase in NMSC incidence with duration of immunosuppression was observed, 
indicating that immunosuppression is the key factor facilitating the development of 
NMSC in OTR 9, 39, 44-48. Incidences of NMSC in OTR vary to a large extent from a 4- to 
250-fold increased risk compared with the general population 39, 43. Variability in the 
incidences between these studies may reflect that many factors play a role in NMSC 
development, including population differences in race, skin type, age, UV exposure 
and mean duration and type of immunosuppression. Furthermore, the variability in 
outcome may result from differences in the methods employed to determine the 
occurrence of NMSC. Some studies have reported incidence, others cumulative 
incidence, others relative risk, or the factor by which NMSC incidence is increased in 
OTR compared to a specified reference population. Yet others did not report the 
statistical methods used. We selected the population-based studies with high quality 
statistical analyses and summarized the data in Figure 3 and Table 1. 
 Several studies measured cumulative incidence of cutaneous SCC and BCC after 
organ transplantation (Figure 3). Bouwes Bavinck et al 44 and Ramsay et al 48 found 
equivalently high risks for SCC in the tropical Australian state of Queensland, with a 
cumulative incidence at 20 years of approximately 60% for both SCC and BCC (Figure 
3). A study from Spain 46 only demonstrated cumulative incidence up to 10 years post-
transplant, but showed a similar cumulative incidence compared with Australia (Figure 
3). Meanwhile studies from the UK 49 and the Netherlands 39 found lower 20-year 
cumulative incidence rates for SCC of 34% and 40% respectively and 20-year 
cumulative incidence rates for BCC of 7% and 10%. 
 Another measure to express the incidence is the incidence rate per person years. 
The highest incidence rate that has been observed was 379 per 1,000 person years at 
risk for SCC and 127 per 1,000 person years for BCC in heart transplant recipients (HTR) 
in Australia 50 (Table 1). Studies from Spain, UK and The Netherlands found an incidence 
for SCC of 29/1,000, 71/1,000 and 7.6/1,000 person years respectively and for BCC of 
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26/1,000, 22/1,000 and 3.3/1,000 person years 39, 45, 51. To allow a proper comparison the 
incidence in the UK study (71/1,000) should be decreased by a factor 6, since this was 
the average number of cumulative SCC scored for given individuals 51. 
 Other studies have provided incidence rates compared with the general 
population, presenting population-based standardized incidence ratios (SIR) 14-16, 27, 47. 
To measure the SIR accurately, it is of importance that all cutaneous SCC and BCC are 
accurately reported to a comprehensive national cancer registry. The population-
based SIR that were available for post-transplant SCC and post-transplant BCC are 
illustrated in Table 1. Based on these studies the risk for SCC is approximately 70 times 
increased and the risk for BCC 7 times increased compared with the general population.
 Besides the incidence of NMSC it is of importance to determine the number of 
NMSC tumors per individual to measure disease burden and to design a more rational 
follow-up of these patients. Bouwes Bavinck et al 44 found an average of 10 NMSC 
tumors per OTR in Australia, Bordea et al 51 an average of 6 tumors per OTR in the UK, 
and Blohme et al 38 reported two OTR in Scandinavia with over 100 skin lesions each. 
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The prevalence of OTR with multiple skin lesions was shown to vary between studies 
from 26 to 80%, which may be due to geographic differences, but also due to 
differences in length of follow-up and patient age 27, 33, 38, 39, 52-55. According to a 
Scandinavian study, 25% of patients with a first NMSC have a second lesion within 13 
months, and 50% have a second lesion within 3.5 years 27. Liddington et al reported a 
mean interval of 15 months between detection of the first and second NMSC, and 11 
months between the second and the third NMSC 42. A French study showed that 34% 
of HTR and 52% of KTR with a first SCC developed a subsequent SCC within 3 years 
after the first SCC. After 5 years these percentages had risen to 64 and 67% in HTR and 
KTR, respectively 52. A study from New Zealand showed that virtually all KTR with skin 
cancer developed multiple NMSC, with incidences of 30%, 50%, 60% and 80% at 1, 2, 
3 and 5 years, respectively, after the first skin cancer 53. These percentages are high 
compared with the general population, since the 3-year cumulative risk of a 
sub sequent SCC after a first SCC in the general population has been described to be 
18% 56. While the risk for secondary SCC has been investigated in OTR, the risk of a 
subsequent BCC after the first BCC has not been reported in OTR. In the general 
population, approximately 50% of patients routinely treated for BCC developed 
multiple primary BCC during 10 years of observation 57, 58. A meta-analysis of 
7 independent studies showed a mean 3 year risk of 44% after an initial diagnosis 
of BCC 56.
Non-cutaneous malignancies
Large population-based cohort studies have reported that a range of non-cutaneous 
malignancies (NCM) occurs at increased rates in OTR, with an overall 2- to 5-fold 
increased cancer risk compared with the general population 13, 14, 16-18. Among NCM we 
also count cancers of the mucous tissues. Anogenital dysplasias, comprising carcinoma 
of the vulva and anus, were 23- and 7-fold increased, respectively. The rate of lym-
phoproliferative disorders has been reported to be increased with a SIR of 7 for 
non-Hodgkin lymphoma 13, 14, 17, 18 and 4, 3 and 2 for Hodgkin’s lymphoma 13, 14, 17, 18, 
multiple myeloma 13, 14, 17 and leukemia 13, 14, 17, respectively. Rates of liver and stomach 
cancer as well as epithelial lung cancer were approximately 2-fold increased. Most 
other common epithelial cancers, such as breast, prostate, ovarian and colorectal 
cancers, occurred at the same rate as in the general population 13, 14, 16-18. Follow-up 
times of these studies were approximately 20 years.
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Association between skin cancer and non-cutaneous malignancies in organ 
transplant recipients 
In immunocompetent patients with cutaneous SCC, a 2-fold increased risk of NCM has 
been observed 59-61. However, other studies did not show an overall increased risk of 
NCM in SCC patients 62. In BCC patients, the overall cancer incidence has also been 
reported to be significantly elevated 61, 63, 64. Vice versa, the occurrence of SCC as 
second primary malignancy after any NCM has been described to be increased in the 
general population 65. Furthermore, Brennan et al showed an increased risk of NMSC 
after non-Hodgkin lymphoma 66. The fact that cancer patients were at an increased 
risk for new primary cancers, may be explained by a common pathogenic pathway 
involved in the different types of cancer, and lifestyle factors of the patient, such as 
UV exposure, smoking and diet 67. It is unknown whether the development of 
cutaneous SCC and/or BCC is associated with an increased risk of NCM in OTR as well, 
like in immunocompetent patients.
Risk factors for skin cancer in organ transplant recipients
The best-studied factors that appear to favor development of skin cancer are age at 
transplantation, male sex, fair skin type, high UV exposure, the presence of actinic 
keratoses, and the length and level of immunosuppression. Few investigators found 
all of these to be independent risk factors, but they were consistently reported across 
a wide range of studies 27, 28, 40, 44, 46, 47, 51, 68-71. In a prospective study examining the first 3 
years of immunosuppression in KTR from Spain, Ferrándiz 69 found a cumulative risk 
for NMSC of 18% with age at transplantation and occupational UV exposure being 
significant risk factors. Naldi from Italy 70 found age at transplantation and male sex to 
be the most important risk factors. Also from Italy, Caforio 68 found age at transplanta-
tion, fair skin type, high UV exposure, actinic keratoses and a high rejection score to 
be independently associated with an increased SCC risk in HTR. Since cumulative im-
munosuppressive load is difficult to calculate, a high rejection score in the first year 
post-transplantation was proposed to be a useful predictor for patients at risk. 
However, other studies did not confirm the association between number of rejections 
and development of NMSC in OTR 51, 70, 72, 73. 
 The presence of human papillomavirus (HPV) has been suggested to be a risk 
factor for SCC, although a causative role for HPV in skin cancers in OTR has not been 
proven. HPV DNA was found in 65% to 90% of skin cancers that developed in OTR 74-76, 
while in immunocompetent individuals approximately in 40% of the skin cancers HPV 
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DNA was found 75, 77, 78. The rate of HPV detection in normal sun-exposed skin has been 
described to be higher in OTR with skin cancer compared with those without skin 
cancer. This supports the hypothesis that OTR have persistent HPV infection that 
predisposes to oncogenesis 79. However, HPV is also frequently present in the hair 
follicles and normal skin from OTR 80. Furthermore, comparing OTR with and without 
skin cancer, others have shown an equally high prevalence of HPV DNA in keratotic 
skin lesions in both groups of patients, and a similar detection rate and spectrum of 
HPV infection in hyperkeratotic papillomas and actinic keratoses 81. Recent 
 epidemiological 77, 82 as well as experimental studies 83 have suggested a possible 
synergetic effect between HPV infection and UV radiation in carcinogenesis of the 
skin. Two major risk factors for skin cancer in OTR, UV exposure and prolonged 
 immunosuppressive therapy, will be discussed in more detail below.
Ultraviolet radiation
UV exposure is the primary risk factor for NMSC both in the general population 84 and 
in OTR 68, 85. This is illustrated by an increased risk of skin cancer in patients with high 
sun exposure before organ transplantation 46, 68, 86. Furthermore, the cumulative risk for 
SCCs was reported to be greater in countries with a high level of UV radiation, such as 
Australia (34% at 10 years) 44 or Spain (33% at 10 years) 46, compared with countries 
with limited sun exposure, such as the Netherlands and Norway (7% at 10 years) 39, 47. 
The preferential location of SCC on sun-exposed areas further supports the pathogenic 
role of sunlight 39. It is assumed that the oncogenic properties of UV radiation are due 
to a direct mutagenic effect and an immunosuppressive effect. It has been shown 
that UV light is a keratinocyte mutagen, which can cause mutations, such as cytosine 
to thymine transitions at cytosine-containing dipyrimidine sites 87. When these 
mutations affect the function of sufficient oncogenes, tumor-suppressive genes, and 
important housekeeping genes, outgrowh of neoplastic keratinocytes can occur. 
UV-induced immunosuppression is a highly complex process and several different 
pathways are involved 84, 88-90. In particular, low doses of UV light radiation reduce the 
number and function of epidermal Langerhans’ cells, impairing their role in the 
immune response against virus-infected cells and transformed cells. UV light radiation 
can also induce systemic immunosuppression by inducing the generation of soluble 
mediators, notably cis-urogenic acid and interleukin-10 84, 88-90. 
Immunosuppressive therapy
The maintenance immunosuppressive therapy in OTR usually consists of prednisone 
in combination with immunosuppressants such as azathioprine (purine-antagonist), 
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mycophenolate mofetil (inosinemonophosphatehydrogenase-inhibitor), cyclosporine 
or tacrolimus (calcineurine-inhibitors), and sirolimus or everolimus (mTOR-inhibitors). 
Acute rejection in OTR will usually be treated with high doses of polyclonal antibodies 
against thymocytes (ATG) and monoclonal antibodies against CD3 (muromonab). 
In hairless mousemodels it has been shown that classical immunosuppressants, 
azathioprine and cyclosporine, speeds up UV carcinogenesis and adversely affects 
repair of UV-induced DNA-damage in skin cells 91. Moreover, Azathioprine has been 
reported to induce selective UVA photosensitivity, thus increasing the DNA damage 
caused by UV exposure 92. Cyclosporine can impair UV-induced apoptosis, which also 
increases the risk of skin cancer 93. In contrast to the traditional immunosuppressants, 
mycophenolate mofetil and sirolimus, did not enhance UV carcinogenesis 94. Although 
mycophenolate mofetil, like azathioprine, interferes with purine synthesis, it does not 
give rise to incorporation of (6-thio-guanine) pseudobases that photosensitize DNA. 
Furthermore, sirolimus operates through an entirely different mechanism by blocking 
mTOR (mammalian target of rapamycin), which has been shown to have an 
antiangiogenic effect, resulting in impaired tumor outgrowth 94, 95. However, so far, 
there is no convincing clinical evidence for differences in oncogenic potential 
between the specific immunosuppressive agents. Comparison of incidence rate by 
type of immunosuppressive drug is difficult, because the regimen of immuno-
suppressive agents is strongly associated with the time period in which the patient is 
transplanted. A recent study showed that treatment with azathioprine was associated 
with a significant increased risk for SCC 96. Evidence also suggests that sirolimus, a 
mTOR inhibitor, compared with other immunosuppressive medications may confer a 
decreased risk of skin cancer 97, 98. 
 Rather then the type of immunosuppressive agent, the total level of immuno-
suppression may determine the risk of skin cancer 44, 70, 99, 100. In a prospective trial in 
which patients were randomly assigned, KTR receiving low dose cyclosporine regimen 
had a significantly lower incidence of secondary skin cancers compared with the 
patients using normal dose cyclosporine 68. Furthermore, the greater degree of 
 immunosuppression after heart transplantation, to prevent the catastrophic rejection 
of the donor organ, has been shown to result in a higher incidence of skin cancer in 
HTR compared with KTR 47, 54, 101, 102. 
chapter 1
21
Other skin diseases in organ transplant recipients
Besides skin cancers, also benign skin tumors 28, 39, 44, 47 and fungal, viral, and bacterial 
skin infections 103-105 are frequently observed in OTRs. The prevalence of skin infections 
is very high and several studies have described that 55% to 97% of OTR do have some 
type of infection 104-108. The spectrum of skin infections differs according to the post-
transplant time period 105. During the first month post-transplant, infections mainly 
result from surgical interventions 103. After the first month post-transplant, infectious 
skin diseases are more frequently a result of severe immunosuppression, manifesting 
in infections with herpes viruses (herpes simplex virus, varicella-zoster virus, cyto-
megalovirus, Epstein-Barr virus), yeasts (Candida), and bacteria 105. Six months and 
more after transplantation, the chronic and progressive infections start to exert 
clinically significant effects 103, 105, of which infections with HPV have been most 
frequently described 79, 103, 109. Compared with the large number of studies focusing on 
the development of malignant and benign skin tumors in OTR, infectious and 
inflammatory skin diseases were only studied scarcely 79, 103-109. 
Aim and structure of the thesis
The aim of the studies presented in this thesis is broadly twofold. Firstly, we aimed to 
determine the pattern and frequency of SCC, BCC, NCM and skin diseases in OTR 
transplanted in the Leiden University Medical Center (descriptive epidemiology). 
Increasing the recognition of these clinical complications can help to provide a 
rationale for more extensive follow-up of OTR and allow more rapid clinical 
interventions. Secondly, we aimed to identify causes for the increased incidence of 
malignancies in OTR   (analytic epidemiology). Identification of the risk factors involved 
in the development of SCC, BCC, and NCM may increase the efficiency of OTR 
follow-up. 
Chapter 2 describes the standardized morbidity ratio of NCM, SCC and BCC in KTR 
who had received a transplantation at the Leiden University Medical Center between 
1966 and 2006. 
Chapter 3 determines the risk to develop a second SCC or BCC following the 
occurrence of the first SCC or BCC in a cohort of KTR and studies risk factors for the 
development of subsequent SCC or BCC.
Chapter 4 investigates the frequency and number of registered skin diseases in OTR 
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transplanted between 1966 and 2006 in a single centre, which were diagnosed 
between 1994 and 2006. Furthermore, the relative contributions of the different skin 
diseases in relation to the number of years after transplantation were studied.
Chapter 5 compares the cumulative incidence of skin cancer in SPKTR with the 
cumulative incidence of skin cancer in KTR in relation to potential risk factors of skin 
cancer. 
Chapter 6 studies the risk of NCM after the development of cutaneous SCC and/or 
BCC in KTR. 
Chapter 7 studies whether the number of transplantations, as a marker for the 
rejection status of the patient, is associated with the risk of the development of 
malignancies. The risk for cutaneous SCC and other malignancies are analyzed 
separately. 
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In a long-term cohort study, we calculated cancer incidences and survival rates after 
the development of these cancers in kidney-transplant recipients. The cancer 
incidences were compared with those in the general population. The occurrence of 
cancer was recorded in all patients who received a kidney transplantation between 
1966 and 2006. The median follow-up time was more than 9 years with a maximum of 
almost 40 years. Altogether 327 (17%) of 1906 patients developed cancer after trans-
plantation: 142 (7%) had non-cutaneous malignancies; 178 (9%) cutaneous 
squamous-cell carcinomas and 138 (7%) basal-cell carcinomas. The cumulative 
incidence of any cancer was 13%, 33% and 47% after 10, 20 and 30 years, respectively. 
The incidences of cancers of the oral cavity, stomach, female genital organs, kidney, 
thyroid gland, leukemias and lymphomas, and cutaneous squamous-cell carcinoma 
were significantly increased with a highest standardized morbidity ratio of 40 for 
cutaneous squamous-cell carcinomas. Survival rates after non-cutaneous malignancies 
were 57%, 43% and 36% and after non-melanocytic skin cancer 99%, 90% and 77% 
after 1, 3 and 5 years, respectively. The increased incidence of non-cutaneous 
malignancies after kidney transplantation is associated with a high mortality. 





There is abundant evidence that the incidence of cancer is increased in kidney- 
transplant recipients (KTR) 1-4. The risk for the most common malignancies, e.g. colon, 
lung, stomach, oesophagus, pancreas and ovary cancers is, generally, threefold 
increased in KTR compared with the general population 1, 3, 5. Cancers associated with 
viral infections, such as cervical cancer, lymphoma 6, 7, Kaposi sarcoma 8, 9 and skin 
cancers, in particular cutaneous squamous-cell carcinomas (SCC) 10-13 appear to be 
increased the most. Recently, thyroid cancers were added to the group of high cancer 
risk following organ transplantation 14. However, not all cancers are increased in the 
transplant population 5, 15. Breast 5, 16 and prostate 5 malignancies are two of the most 
common cancers in the general population that are not increased in KTR. Despite 
considerable evidence that the incidence of cancer is increased in KTR, a recent study 
of Kiberd et al. showed that the overall mortality rates are not substantially different 
compared with the mortality in the general population 17.
 The aim of this study was to estimate the incidence of non-cutaneous malignancies 
(NCM) and cutaneous SCC and basal-cell carcinoma (BCC) in all patients who had 
received a kidney transplantation at the Leiden University Medical Center (LUMC) and 
to compare this incidence with the incidence in the general Dutch population. We 
also assessed the survival rate of KTR who had NCM before transplantation and the 




We performed a retrospective cohort study of all 1906 patients who received a first 
kidney transplantation at the LUMC between March 1966 and January 2006. Most of 
these patients were regularly followed at the department of Nephrology. When 
patients had cutaneous problems they were also seen at the department of 
Dermatology. At each visit to the skin clinic the entire skin was checked for skin 
problems. Special attention was focused on the possible presence of keratotic skin 
lesions and skin cancers. The study adhered to the Declaration of Helsinki Principles 
and the medical ethical committee of the LUMC had approved the study design.
 Between 1966 and 1986, the immunosuppressive treatment of KTR in our clinic 
consisted of duo therapy with prednisolone (P) and azathioprine (Aza), but shortly 
incidence of cancer in kidney transplant recipients: a long-term cohort study in a single center
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after 1986 all new KTR were immunosuppressed with P and cyclosporine A (CsA). After 
1996 triple therapy became the treatment of choice where, initially, most new KTR 
were treated with P, mycofenolatemofetil (MMF) and CsA and later with P, MMF and 
tacrolimus (Tac).
 KTR, in whom acute graft rejections were observed, were usually initially treated 
with methylprednisolone. When this therapy was not sufficient to prevent further 
rejection a second rejection treatment with anti-thymocyte globulin (ATG) and a third 
rejection treatment with once more methylprednisolone were given. In exceptional 
cases muronomab-CD3 (OKT3) was given when a fourth rejection treatment was 
needed. With the exception of some rare patients, induction treatments with ATG 
and/or OKT3 were not given to KTR who were transplanted in the LUMC. Starting in 
2000, however, induction treatment with basiliximab became common practice.
Collection of data
Data recorded for all KTR included the date of the first and subsequent  transplantations, 
dates of birth, sex, and the dates of cancer, death or last follow-up. The main outcomes 
of cancer were the diagnoses of NCM and cutaneous SCC and/or BCC and were 
collected from the computerized oncological registry of the LUMC, the database from 
the department of Pathology and the national histological database (PALGA). PALGA 
is an acronym, literally translated: pathological anatomy national automated archive. 
Excerpts of all histopathology and cytopathology reports are generated automatically 
at the participating laboratories and transferred to the central databank. Both the 
decentralized systems and the central system perform checks on the quality and 
completeness of excerpts. This central databank contains about 42 million records on 
almost 10 million patients 18. The medical charts were also hand searched for the 
diagnosis of cancer. Premalignant and in situ lesions were excluded. Follow-up data 
were collected until June 2007, the arbitrary end of the study.
 The diagnoses of NCM were based on the International Classification of Diseases 
10th Modification Diagnoses Codes (ICD-10). NCM were categorized into carcinomas, 
lymphomas, leukemias, sarcomas and an “undefined” group. Locations of the NCM 
were categorized as: head and neck; digestive organs; lower respiratory system; bone 
and soft tissues; skin; breast; female genital organs; male genital organs; urinary tract; 
central nervous system; endocrine glands; blood, bone marrow and lymph nodes; eye 
and orbit, other sites; and unknown primary site. Different than in the ICD-10 
classification we classified lip carcinomas as cutaneous SCC or BCC and not as NCM.
 Statistical data for cancer per 5 year age categories were obtained from the 
Eindhoven Cancer Registry for the period 1966-1988 and from the Netherlands Cancer 
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Registry for the period 1989-2006. There are eight comprehensive cancer centers in 
the Netherlands who collect data of new cancer patients, such as tumor type, 
incidence date and stage. The Netherlands Cancer Registry was established in 1989 
and provides incidence data on a national level. This registry contains data on nearly 
all new cancer cases in the Netherlands. The data are collected by co-workers of the 
regional comprehensive cancer centers.
Statistical analyses
Kaplan Meier survival analyses were used to estimate the cumulative incidences of 
cancer after transplantation. As opening dates for these analyses we used the date of 
the first transplantation; as closing dates we used the date of diagnosis of the first 
specific malignancy, the date of the patient’s death or the date of last follow up. 
Malignancies before transplantation were not considered in these analyses.
 The incidence of cancer in the KTR after transplantation was compared with the 
incidence in the general population by calculating standardized morbidity ratios 
(SMR) with 95% confidence interval and was matched for age, sex and time period in 
which the malignancy had occurred. The SMR for haematolymphopoetic malignancies 
was calculated for the total group since these malignancies were not registered for 
the different subcategories during the earlier periods. The expected number of BCC 
could not be calculated, since this type of cancer is not routinely registered in the 
Netherlands. If a patient had developed two NCM after transplantation, person years 
between the transplantation and the first NCM and between the first and second 
NCM were calculated. In patients with multiple cutaneous SCC and BCC only the first 
occurrence after transplantation was considered.
 Kaplan Meier survival analyses were used to estimate survival of the patients after 
cancer. As opening dates for these analyses we used the date of the specific 
malignancy; as closing dates we used the date of the patient’s death or the date of last 
follow up. A Cox proportional hazard analysis was used to calculate the chance of 
decreased survival after transplantation of the patients with a pre-transplant 
malignancy compared with the other patients. Survival of the patients was not 
compared with survival in the general population, because in the KTR the stage of the 
disease, which is essential for the comparison of survival, was not systematically 
collected.
 The statistical calculations were performed using SPSS for Windows version 16.0.1 
(SPSS Inc, Chicago, IL) and Stata/SE for Windows version 10.1 (Stata Corp LP, College 
Station, Texas).




Baseline characteristics of the KTR
The median age at transplantation of the 1906 KTR was 43.9 years (range 3.8 – 77.5) 
with a median follow up of 9.2 (range 0 -39.9) years. A total of 1175 (61.6%) out of 1906 
KTR were male. Altogether 50 (3%) of the patients already had a history of cancer 
before transplantation and 327 (17%) developed cancer after transplantation: 142 (7%) 
had NCM; 178 (9%) cutaneous SCC and 138 (7%) BCC.
 The cumulative incidence of any malignancy after transplantation was 13% 
after 10 years, 33% after 20 years and 47% after 30 years (Figure 1). Table 1 shows 
 characteristics of the 50 KTR with cancer before the transplantation and Table 2 of 
the 327 KTR who developed their first cancer after the kidney transplantation.
Description of malignancies
Forty-one of the 53 malignancies (in 50 patients) before transplantation were NCM, of 
which 11 were a malignancy of the kidney (Table 1). Five out of 41 patients with a first 
NCM before transplantation also had a second NCM before transplantation (Patients 1 
to 5 in Table 3). In 3 of these 5 patients there was a malignancy of both kidneys.
 Of the 46 NCM before transplantation 42 were carcinomas, 1 was a non-Hodgkin 
lymphoma, whereas the cellular type was undefined in 3 NCM (Tables 1 and 3). The 
most frequent locations of the first and second NCM before transplantation were the 
urinary tract (17 times), followed by the digestive organs (7 times), breast (7 times) and 
the female (6 times) and male (4 times) genital organs (Tables 1 and 3).
After the kidney transplantation a total of 142 KTR developed a NCM (Table 2), 
of which 6 had already a NCM before transplantation (Patients 6 to 11 in Table 3). 
Of the 136 patients with a first NCM after transplantation 9 developed a second NCM 
(Patients 12 to 20 in Table 3).
 Of the 151 NCM after transplantation 112 were carcinomas, 8 leukemias, 
22 lymphomas and 2 sarcomas whereas the cellular type was undefined in 7 NCM 
(Tables 2 and 3). The most frequent locations of the first and second NCM after 
 transplantation were the digestive organs (45 times), followed by the respiratory 
tract (15 times), the urinary tract (14 times), the female genital organs (12 times), 
bone marrow (12 times) and the male genital organs (11 times). The leukemias 
consisted of 4 acute myeloid leukemias, 1 chronic myeloid leukemia and 3 chronic 
lymphocytic leukemias (2 B-cell, 1 T-cell). The lymphomas consisted of 20 non- 




 Cutaneous SCC and BCC were, by far, the most frequently diagnosed cancers after 
transplantation (Table 2). SCC was diagnosed in 178 and BCC in 138 patients, 
respectively. The maximum number of SCC in one patient was 68 and the maximum 
number of BCC in one patient was 28. In total there were more than 1800 SCC and BCC 
in these patients. For this study, however, only the first SCC and BCC were 
considered.
 In total, 29 SCC and 8 BCC of the lip had been diagnosed in 31 KTR. In 8 of these 
patients SCC of the lip was the first presentation of SCC and in 7 patients BCC of the 
lip was the first presentation of BCC.
incidence of cancer in kidney transplant recipients: a long-term cohort study in a single center
2Figure 1   Cumulative incidence of any malignancy, non-melanocytic skin cancer 
(NMSC), squamous-cell carcinoma (SCC), basal-cell carcinoma (BCC) 
and non-cutaneous malignancy (NCM) in kidney transplant recipients. 

















Type of skin cancer 0 10 20 30
All cancer 1857 793 271 55
NMSC 1898 818 283 56
SCC 1904 844 301 63
BCC 1898 850 323 69
NCM 1865 863 354 85
Numbers of KTR at risk at the specied 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Incidence of cancer in KTR compared with the general population
The SMRs adjusted for age, sex and the period of occurrence of the cancers after 
kidney transplantation are displayed in Table 4. Compared with the general population 
the risk to develop NCM was 1.6 times increased in KTR. The highest risks were found 
for thyroid carcinoma and haematolymphopoetic malignancies with SMRs of 9.5 
and 4.1, respectively (Table 4). NCM of the oral cavity, stomach, female genital organs 
and kidney were also significantly increased compared with the general population 
(Table 4). The risks of prostate carcinoma and breast cancer in KTR were slightly 
decreased, but statistical significance was not reached (Table 4).
 The risk of cutaneous SCC was 40 times, the risk of Kaposi sarcoma 21 times and 
the risk of malignant melanoma 3 times increased compared with the general 
population (Table 4). Because of incomplete registration of BCC in the general 
population, the SMR of BCC could not be calculated.
Survival of the patients after malignancies
Altogether 107 (75%) out of the 142 patients who had developed 1 or 2 NCM after 
transplantation and 116 (50%) out of the 231 patients who had developed skin cancer 
had died (Table 5). The survival rates after the diagnosis of NCM were 57%, 43%, 36% 
and 22% after 1, 3, 5, and 10 years, respectively (Table 5). Especially the diagnoses of 
stomach cancer and lung cancer were associated with a poor prognosis (Table 5). 
The patients with skin cancer survived much longer after the diagnosis of the first skin 
cancer with survival rates of 99%, 90%, 77% and 57% after the same time periods, 
respectively (Table 5).
 The survival rate after transplantation of the 41 patients who had a history of a 
malignancy before transplantation was similar compared to the KTR without NCM 
before transplantation. The hazard ratio with 95% confidence interval after adjustment 
for age and sex to die after transplantation for the patients with NCM before 
 transplantation was 0.76 (0.46;1.3).
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incidence of cancer in kidney transplant recipients: a long-term cohort study in a single center
2Table 4   Standardized morbidity ratios adjusted for age, sex and time period  
for different types of cancer in kidney-transplant recipients restricted to  
malignancies which developed after transplantation.
































 1.3  (0.85;2.0)
Bone and soft tissue (sarcoma) 1 1.21  0.83 (0.11;5.9)
Breast 8# 15.02  0.53 (0.26;1.1)
Female genital organs 12 5.01  2.4 (1.4;4.2)
Male genital organs 



















Central nervous system 2 1.72  1.2 (0.29;4.7)
Endocrine glands







Haematolymphopoetic 30 7.41  4.1 (2.8;5.8)
Unknown primary site 5 3.37  1.5 (0.62;3.6)
All first and second non-cutaneous 
malignancies after transplantation together










    ---
 39.6 (34.2;45.9)












All first and second non-cutaneous 
malignancies and first cutaneous 
squamous-cell carcinoma and melanoma 
together
339 102.45  3.3 (3.0;3.7)
$All malignancies were carcinomas unless otherwise indicated. 
*  All first and second non-cutaneous malignancies but only the first cutaneous squamous-cell carcinoma  
after transplantation were counted. Malignancies before transplantation were not counted.
** SMR = standardized morbidity ratio; CI = confidence interval.
#32 malignancies of the digestive organs were observed in 31 patients; 12 colon carcinomas in 11 patients; 
8 breast cancers in 7 patients; and 152 non-cutaneous malignancies were observed in 142 patients.
44
chapter 2
Table 5   Survival rates of the patients after the diagnoses of the most frequently 
occurring malignancies after kidney transplantation.
Survival rate  
at different time periods after 
the malignancies (%)






















































Breast 7 5 (71) 86 38 38 38
Female genital organs 12 7 (58) 92 83 67 48
Male genital organs 





































































All patients who developed  
non-cutaneous malignancies after 
transplantation together





































$All malignancies were carcinomas unless otherwise indicated. 




This long-term cohort study showed that 30 years after transplantation almost 50% of 
the KTR had developed at least one type of cancer. Cutaneous SCC were, by far, the 
most frequently occurring cancers, but survival rates of the patients with non- 
cutaneous malignancies were much lower. Of special interest was the high incidence 
of thyroid carcinoma which was reported only once before in the literature 14. 
The prognosis of the patients with non-cutaneous malignancies before the first 
 transplantation was comparable to the patients without cancer before the 
 transplantation, but it should be noted that these patients had no signs of active 
malignant disease at the time of transplantation.
 Cancers of the oral cavity, stomach, female genital organs, kidney, thyroid gland, 
as well as leukemias, lymphomas, cutaneous squamous cell carcinoma, Kaposi’s 
sarcoma and malignant melanoma occurred 2 to 40 times more frequently compared 
with the general population. Common epithelial cancers, such as colon and lung 
cancer were equally frequently seen in KTR and prostate and breast carcinomas were 
slightly less commonly seen in KTR compared with the general population. The SMRs 
of our study are largely in agreement with other studies 2, 3, 14, 19, showing an overall 
increased risk of malignancies.
 Studies in KTR showing survival rates after the diagnosis of cancer are scarce and 
usually have a shorter follow-up time. Vegso et al showed in Hungary a 5-year survival 
of 38% after NCM and of 76% after NMSC 6. A study from Italy showed 1- and 2-year 
survival rates of 64% and 51% for NCM versus 89% and 89% for NMSC 20. These data are 
largely in agreement with the 1-, 3- and 5-year survival rates of 59%, 45% and 39% and 
99%, 90% and 77% for NCM and NMSC in our study.
 A strength of our study is the long follow-up period with a median follow-up time 
of more than 9 years and a maximum follow-up of almost 40 years, which is much 
longer compared with previous studies studying cancer incidence rates 2, 3, 19, 21, 22. 
While the long follow-up period is in some ways an advantage, it is also subject to 
“period effects” i.e. changes in immunosuppressive regimen, cancer screening 
practice and treatment have all changed dramatically over time. Thus patients with 
longer follow-up may be less comparable to those with shorter follow-up for reasons 
other than duration of observation. Another potential weakness of our study is the 
relatively low power caused by inclusion of patients of a single center so that only 
the SMRs of the most frequently occurring malignancies could be reliably calculated. 
In addition, our study was not large enough for a direct comparison of the survival 
rates of the different malignancies with the non-transplanted population, since the 
incidence of cancer in kidney transplant recipients: a long-term cohort study in a single center
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malignancies were very diverse, both regarding the type of malignancy and the stage 
of the disease, which factors have an important impact on survival. Finally, medical 
doctors are following KTR more intensively compared to the general population, 
which may introduce surveillance bias.
 In conclusion, after kidney transplantation, a wide variety of cancers across a large 
number of organ systems can occur. Many of these cancers occur more frequently 
than expected based on the occurrence of these cancers in the general population. 
Because of the high mortality rate of the NCM and the high morbidity rate of 
cutaneous SCC and BCC, prevention of cancer after transplantation should be a major 
focus of future research.
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The risk of skin cancer is highly increased in kidney-transplant recipients, but the risk 
of subsequent skin cancers is less well studied. The aim of this study was to estimate 
the cumulative incidence of subsequent squamous- and basal-cell carcinomas and to 
analyze potential risk factors. All histologically confirmed skin cancers between 1966 
and 2006 were included in the study and counted. Cumulative incidences of 
subsequent squamous- and basal-cell carcinomas were calculated with Kaplan Meier 
survival analyses. For the analyses of risk factors we used Cox proportional hazard 
analyses. A total of 239 (13%) out of 1906 kidney-transplant recipients developed skin 
cancer of whom 222 were diagnosed in our hospital. Altogether 167 (75%) of these 
222 patients developed multiple skin cancers. The cumulative incidence of a second 
skin cancer increased from 32%, 1 year to 59%, 3 years and 72%, 5 years after the first 
skin cancer. Kidney-transplant recipients who started with squamous-cell carcinoma 
mainly developed squamous-cell carcinoma and recipients who started with basal-cell 
carcinoma mainly developed basal-cell carcinoma as second skin cancer. Immuno-
suppression with azathioprine in combination with prednisone was associated with a 
significantly increased risk of subsequent squamous-cell carcinomas but not with 
subsequent basal-cell carcinomas. Skin cancer multiplicity is very common in kidney-
transplant recipients. Patients with a first skin cancer are at increased risk for more skin 




The highly increased risk of non-melanocytic skin cancer (NMSC) in organ-transplant 
recipients (OTR) due to long-term use of immunosuppressive drugs has been frequently 
reported (1-8). The cumulative incidence of NMSC rises with increasing time after 
 transplantation (1,2,6,9-11). Most studies, however, focused only on the first squamous- 
cell carcinoma (SCC) or basal-cell carcinoma (BCC). The risk to develop subsequent SCC 
or BCC in OTR has been scarcely studied (5,11-13). A Scandinavian study showed that 
25% of OTR with a first NMSC will develop a second lesion within 13 months, and 50% 
within 3.5 years (5). A British study reported a mean interval of 15 months between 
detection of the first and second cancers, and 11 months between the second and 
third (13). A French study showed that 34% of the 67 heart-transplant recipients and 
52% of the 121 kidney-transplant recipients (KTR) with a first SCC developed a 
subsequent SCC within 3 years after the first SCC. After 5 years these percentages had 
risen to 64% and 67% in HTR and KTR, respectively (12). A recent study in New Zealand 
showed that virtually all 96 KTR with skin cancer developed multiple NMSC. After 1 year 
approximately 30%, after 2 years 50%, after 3 years 60% and after 5 years 80% had 
developed subsequent NMSC after the first skin cancer (11). Compared with the general 
population these percentages are very high, since the 3-year cumulative risk of a 
subsequent SCC after a first SCC in the general population is 18% (14). The risk of a 
subsequent BCC after the first BCC has not been reported in OTR. In the general 
population, nearly 50% of patients routinely treated for BCC developed multiple primary 
BCC during 10 years of observation (15,16). A meta-analysis of 7 independent studies 
showed a mean 3 year risk of 44% after an initial diagnosis of BCC (14). 
 The most important factors that favor the development of SCC after  transplantation 
are older age at transplantation, male sex, fair skin type, high cumulative sunlight 
exposure and length and level of immunosuppression (2,6,8,9,17-21). The risk of BCC is 
more strongly associated with intermittent, intense sunlight exposure (e.g., sunburn, 
childhood exposure) (22,23). Other risk factors for BCC are older age at  transplantation, 
fair skin type and immunosuppressive treatment (2,8,21,24-27). Risk factors for subsequent 
skin cancers are transplantation before 1984, multiple skin cancers at first consultation, 
hazel-light eye color and advanced age at diagnosis of the first skin cancer (11,12). 
 Better understanding of the risk of a subsequent SCC and BCC in KTR would help 
in the design of a more rational follow-up of these patients. The aim of this study was 
to estimate the cumulative incidence of a second SCC or BCC following the occurrence 
of the first skin cancer in a cohort of KTR and to study risk factors for the development 
of subsequent skin cancers. 





Kidney transplantations have been performed in the Leiden University Medical Centre 
(LUMC) since 1966. Until December 2006, a total of 1906 KTR received their first transplant. 
 Most of these patients were regularly followed at the department of Nephrology. 
Those with cutaneous problems were also seen at the department of Dermatology. At 
each visit to the skin clinic the entire skin was checked for skin problems. Special 
attention was focused on the possible presence of keratotic skin lesions and skin 
cancers. Only few patients were primarily followed by dermatologists in other hospitals 
than the LUMC. 
 The following baseline characteristics were recorded for each KTR: sex and dates 
of birth, transplantation, death, or last follow-up. The risk factors studied in the 
patients with multiple skin cancers compared to those with a single skin cancer were 
sex, age, number of years on immunosuppression, country of origin, type of 
maintenance immunosuppressive therapy, induction and rejection therapy, donor 
type (living or cadaver), HLA-mismatching and the year the transplantation had been 
performed. Data about sun exposure and skin type were not collected, because this 
would have been only possible by questionnaire or physical examination in the living 
patients. The study adhered to the Declaration of Helsinki Principles and the medical 
ethical committee of the LUMC had approved the study design.
Data collection: registration of histological diagnoses
All histological diagnoses were systematically computerized at the department of 
Pathology since 1984 and diagnoses before 1984 were computerized retrospectively 
starting with the biopsies performed in 1970. In the period between 1966 and 1970 no 
skin cancers had been diagnosed, which was checked by hand searching in the 
medical charts of the KTR transplanted before 1970. Dates of the biopsies, locations of 
the lesions and the histological diagnoses were documented. Routinely, the initial 
biopsy was followed by an excision and in some cases by a re-excision. In those cases, 
only the first histologically confirmed diagnosis of this specific skin cancer was taken 
into account, to prevent double counting. In-situ carcinomas (Bowen’s disease), 
precursor lesions (actinic keratoses and keratoacanthomas) and skin cancers other 
than squamous-cell and basal-cell carcinoma (e.g. malignant melanoma, Kaposi 
sarcoma and adnex carcinomas) were not considered in this study.
 The country of origin was used as a rough estimation of skin type. Information 
about the initial and maintenance immunosuppressive therapy of the patients with 
chapter 3
53
one and more skin cancers was obtained from the Eurotransplant database. Type of 
induction therapy and the number and type of rejection treatments were collected 
from the flow sheets in the medical charts of the department of Nephrology. For the 
KTR the immunosuppressive treatment initially consisted of duo therapy with 
prednisolone (P) and azathioprine (Aza), but shortly after 1986 all new KTR were im-
munosuppressed with P and cyclosporine A (CsA). After 1996 triple therapy became 
the treatment of choice where, initially, most new KTR were treated with P, mycofeno-
latemofetil (MMF) and CsA and later most new KTR were treated with P, MMF and 
tacrolimus (Tac).
 KTR, in whom acute graft rejections were observed, were almost always initially 
treated with methylprednisolone. When this therapy was not sufficient to prevent 
further rejection a second and third rejection treatment with anti-thymocyte globulin 
(ATG) and once more methylprednisolone, respectively, were given. In exceptional 
cases muronomab-CD3 (OKT3) was given when a fourth rejection treatment was 
needed. With the exception of some rare patients, induction treatments with ATG 
and/or OKT3 were not given to KTR who were transplanted in the LUMC. Starting in 
2000, however, induction treatment with basiliximab became common practice.
The degree of HLA-mismatching for HLA-A, HLA-B and HLA-DR was assessed by 
counting the antigens present in the donor but absent in the recipient.
Statistical analyses
For the characterization of the patients with and without skin cancer we used the 
data of all 1906 patients who were transplanted in Leiden between 1966 and 2006. 
Kaplan Meier survival analyses were used to estimate the cumulative incidences of 
skin cancer after transplantation. As opening dates for these analyses we used the 
date of the first transplantation; as closing dates we used the date of diagnosis of the 
first skin cancer, the date of the patient’s death or the date of last follow up. Skin 
cancers before transplantation were not considered in these analyses. Patients were 
not censored from the analyses at graft failure. Differences between patients with and 
without skin cancer were analyzed by Chi-square for categorical variables and 
Student’s T-tests for continuous variables.
 For the analyses of subsequent skin cancers in patients with skin cancer we used 
the 222 patients with NMSC who were diagnosed at the LUMC. Kaplan Meier survival 
analyses were used to estimate the cumulative incidence of subsequent skin cancers 
in patients with a prior skin cancer. Cox proportional hazard analyses were used to 
identify potential risk factors of NMSC multiplicity. As opening dates for both analyses 
we used the date of the first skin cancer; as closing dates we used the date of diagnosis 
subsequent skin cancers in kidney-transplant recipients
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of the subsequent SCC or BCC, the date of the patient’s death, the date of last follow 
up, the date that they were lost to follow-up, or we used the date of the end of the 
study (June 1, 2007). Some patients had two NMSC at the time that they presented 
themselves with the first NMSC. In these patients the third NMSC was counted as the 
second presentation of NMSC. 
 The initial and maintenance immunosuppressive therapies were categorized into 
three basic treatment groups: duo or triple therapy with Aza in any combination; duo 
or triple therapy with MMF in any combination; and duo therapy without Aza or MMF 
(i.e. a combination of prednisolone with CsA). If no data were available for the 
maintenance immunosuppressive therapy the data of the initial immunosuppressive 
therapy were used. For all our analyses with immunosuppressive therapy, we used the 
sub-categorization of the maintenance therapy because the patients were, generally, 
most prolonged exposed to this regimen. 
 Because ATG and OKT3 exert by far the highest immunosuppressive effect, 
induction and rejection treatments were dichotomized into those with and without 
ATG and/or OKT3. Because the biological effects of ATG and OKT3 are supposed to be 
similar before and after the transplantation, exposures to ATG and/or OKT3 as 
induction or rejection treatment were also combined for our analyses.
 Statistical analyses were performed with SPSS software (version 16.0, SPSS, Chicago, IL). 
Results
Baseline characteristics
Altogether 239 (12.5%) of the 1906 KTR transplanted between 1966 and 2006 had 
developed at least one NMSC. The baseline characteristics of the patients with and 
without NMSC, SCC or BCC are depicted in Table 1. Eight out of the 239 patients (3.3%) 
had developed the first skin cancer before transplantation (2 both SCC and BCC, 6 
only BCC), with a median time of 1.3 years before transplantation (Table 1). The majority 
of the patients with NMSC were transplanted before 1986, whereas patients without 
skin cancer were more frequently transplanted after 1986 (Table 1, P<0.001). The 
follow-up period of the KTR with skin cancer was, therefore, much longer (p = 0.001). 
The sex distribution did not differ between patients with and without skin cancer (p 
= 0.218) (Table 1). In the Cox proportional hazard model older age at transplantation 
was associated with a significantly increased risk of skin cancer (3.6% [95% CI 2.6%;4.7%] 
increase for each additional year of age, P < 0.001). After stratification for time period 
after transplantation this association was also clear in Table 1. The median age at 
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which the KTR developed their first NMSC was 53.3 years. There were 9 patients who 
died of metastases of SCC (5 times the SCC was located on the arm or shoulder and 4 
times the location was in the face, on the ear, or on the skull). None of the patients 
died of BCC.
subsequent skin cancers in kidney-transplant recipients
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Number of patients 1667 239 180 146





















No. of male: N (%) 1019 (61.1) 156 (65.3) 121 (67.2) 96 (65.8)




















Median age at transplantation  








































Median age at first skin cancer 
(years) (25%-75%)
-- 53.3





NMSC, non-melanocytic skin cancer; SCC, squamous-cell carcinoma; BCC, basal-cell carcinoma; 
KT, kidney transplantation. 
* Some patients had both SCC and BCC. This fact is reflected here by overlapping of the numbers of  
patients in these categories.
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 The cumulative incidence of NMSC after transplantation was 9% after 10 years, 
24% after 20 years and 40% after 30 years. For SCC this incidence was 6%, 19%, and 
33% and for BCC 5%, 14% and 24% after these time periods, respectively. This is 
graphically presented in the supplementary Figure.
Subsequent NMSC
Eighty-six out of the 222 KTR who had histologically confirmed skin cancers at the 
LUMC had developed only SCC, 53 only BCC and 83 KTR had developed both SCC and 
BCC during the follow-up time. More than 75% KTR had developed subsequent skin 
cancers. Twenty-four patients presented with 2 or more NMSC at the first presentation 
of whom 6 patients had 3 NMSC. Approximately 60% developed a third and almost 
50% a fourth NMSC. A total of 25 patients (11.3%) developed more than 20 histologically 
confirmed NMSC. The exact numbers of skin cancer are presented in the supplementary 
Table. The median number of NMSC per KTR was 3.0 with a mean of 8.3 (min-max 
1-76), for SCC this was 3.5 and 8.1 (min-max 1-68), and for BCC 2.0 and 3.4 (min-max 
1-28), respectively. Multiplicity was more evident for SCC than for BCC.
 The cumulative incidence of a second NMSC after the first NMSC increased from 
32% after 1 year to 59% after 3 years and 72% after 5 years (Figure 1). The cumulative 
incidences for a second SCC were 31%, 62% and 75%, respectively. The cumulative 
incidences for a second BCC were lower and were 16%, 37% and 51% after these time 
periods, respectively (Figure 1). 
 The distribution of SCC and BCC on the body is presented in Table 2. When patients 
developed only one SCC this tumor was more frequently located on the head and 
neck, whereas subsequent SCC were more common on the hands and fingers. 
Approximately 50% of the BCC were located on the head and neck in both patients 
with only one BCC as patients with subsequent BCC. Patients with one BCC developed 
the tumor more frequently on the hands and fingers and patients with multiple BCC 
developed them more frequently on the trunk (Table 2). 
The risk of SCC and BCC in KTR with SCC or BCC as first NMSC
A total of 127 KTR started with SCC as the first skin cancer. Hundred (78.7%) of them 
developed a second SCC and 41 (32.3%) developed a first BCC at a later time point. 
Altogether 95 KTR started with BCC as the first skin cancer of whom 54 (56.8%) 
developed a second BCC and 41 (43.2%) a first SCC at a later time point. We asked the 
question whether it would be relevant for the risk and type of subsequent skin cancers 
if the first skin cancer would be SCC or BCC.
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Figure 1   Cumulative incidence of second non-melanocytic skin cancer (NMSC), 
squamous-cell carcinoma (SCC) and basal-cell carcinoma (BCC) in 
 respectively 222, 178 and 138 kidney-transplant recipients (KTR). 
The numbers of KTR at risk in relation to the years after transplantation 
are indicated in the table below the figure.
Numbers of KTR at risk at the specied 
time periods after transplantation (yrs)
Type of skin cancer 0 1 3 5 10
All skin cancer 222 143 76 44 12
SCC 169 111 53 30 11
BCC 136 103 65 39 12
58
 Figure 2A shows that KTR who started with SCC mainly developed SCC as second 
skin cancer and Figure 2B shows that KTR who started with BCC mainly developed 
BCC as second skin cancer. After the development of the first SCC in the latter group 
of patients, the risk of subsequent SCC was similar to the risk of subsequent SCC in the 
KTR who started with SCC.
Risk factors for subsequent skin cancers 
The distribution of potential risk factors in the patients with one and those with 
subsequent SCC or BCC and the results of univariate analyses are presented in Table 3. 
Multivariate analyses are presented in Table 4. In both types of analyses maintenance 
immunosuppressive therapy with Aza was associated with the highest risk of subsequent 
SCC, but not of subsequent BCC. Patients who were immunosuppressed with CsA had 
a significantly reduced risk of subsequent SCC compared to patients who were 
 immunosuppressed with Aza (Tables 3 and 4). A potentially decreased risk of MMF 
could not be assessed, because of insufficient patients in this treatment category. 
 In the univariate analyses the time period of transplantation between 1986 and 
1995 was associated with a reduced risk of subsequent SCC (Table 3), but this reduced risk 
disappeared in the multivariate analyses (Table 4). In contrast, the risk of subsequent 
BCC tended to increase in the later time periods, although significance was not 
reached (Table 4). 
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Table 2   Location of tumors by one or multiple skin cancer.
One SCC Two and 
more SCC
p-value One BCC Two and 
more BCC
p-value






































SCC, squamous-cell carcinoma; BCC, basal-cell carcinoma
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 Age at transplantation, which is a risk factor for the first skin cancer, was not a 
statistically significant risk factor for subsequent SCC or BCC (Table 3), although there 
was a trend of an association between older age and skin cancer in the multivariate 
analyses (Table 4). Patients with a longer time between the transplantation and the 
development of the first SCC had an increased risk of developing subsequent SCC, but 
the time between transplantation and the first BCC did not influence the development 
of subsequent BCC (Tables 3 and 4). 
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Figure 2   A. Cumulative incidence of a second non-melanocytic skin cancer 
(NMSC), squamous-cell carcinoma (SCC) and basal-cell carcinoma (BCC) 
in patients with a SCC as first event. The numbers of kidney-transplant 
recipients (KTR) at risk in relation to the years after transplantation are 
indicated in the table below the figure.
Numbers of KTR at risk at the specied time periods 
after transplantation (yrs)
Type of skin cancer 0 1 3 5 10
All skin cancer 127 75 38 25 10
SCC 127 81 39 21 10
BCC 127 107 100 75 48
60
Patients who were transplanted with a kidney of a living donor had an increased risk 
of subsequent BCC compared to patients who received a cadaver kidney (Table 4). 
Donor type did not affect the risk of subsequent SCC. 
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Figure 2   B. Cumulative incidence of a second non-melanocytic skin cancer 
(NMSC), squamous-cell carcinoma (SCC) and basal-cell carcinoma (BCC) 
in patients with a BCC as first event. The numbers of kidney-transplant 
recipients (KTR) at risk in relation to the years after transplantation are 
indicated in the table below the figure.
Numbers of KTR at risk at the specied time periods 
after transplantation (yrs)
Type of skin cancer 0 1 3 5 10
All skin cancer 95 68 38 19 2
SCC 95 87 78 64 30
BCC 95 73 47 27 8
61












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 4   Risk of multiple SCC or BCC in kidney transplant recipients with adjustments 
















































































Type of maintenance immunosuppression
Aza in any combination
MMF in any combination











ATG, anti-thymocyte globulin; Aza, azathioprine; BCC, basal cell carcinoma; CsA, cyclosporine A; MMF, 
mycofenolatemofetil; P, prednisolone; SCC, squamous cell carcinoma; Tac, tacrolimus; OKT3, muronomab-CD3; 
CI, confidence interval.
* Adjusted for age at transplantation, sex, donor type, year of transplantation, time to first skin cancer, ATG or 
OKT3 as induction or rejection treatment and maintenance immunosuppression.
** When there were less than 7 patients in both categories together, the hazard ratio was not calculated. 
Statistically significant hazard ratios are indicated in italic.
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 Male sex and ATG or OKT3 as induction or rejection therapy were not significantly 
associated with an increased risk of subsequent SCC or BCC (Tables 3 and 4). HLA-
mismatching also did not influence the risk of subsequent SCC or BCC (data not 
shown). Country of origin was not analyzed as a risk factor, since all patients with SCC 
originated from the Netherlands and only two of the patients with BCC originated 
from another country, namely China and Turkey, respectively.
Discussion
This study confirms the high risk of subsequent NMSC in KTR who have developed a 
first NMSC. This risk was especially high for SCC but was also substantial for BCC. The 
tumor burden was very high in these patients with 24% of KTR developing 10 or more 
skin cancers within a short time period. The high risk of subsequent SCC was only 
apparent after the appearance of a first SCC: the risk of SCC was much lower in the KTR 
who presented themselves with BCC, but after the appearance of the first SCC 
subsequent SCC appeared equally fast in the latter group.
 The 3-year risks of 59% of NMSC and 62% of subsequent SCC in our study are 
comparable with the risks of 60% of NMSC in New Zealand (11) and 52% of SCC in France 
(12) and the 5 year-risks of 72% of NMSC and 75% of SCC in our study are comparable 
with the risks of 80% of NMSC in New Zealand (11) and 67% of SCC in France (12). The risk 
of subsequent SCC in KTR is much higher compared with the general population, in 
which a 3-year cumulative risk of subsequent SCC of only 18% was calculated (14). 
 There are no previous studies describing the risk of subsequent BCC in KTR. 
The 3-year risk of 37% and the 5 year-risk of 51% of subsequent BCC in our study are 
comparable with previous observations in the general population where a 
meta-analysis of 7 studies between 1972 and 1993 showed a 3-year cumulative risk of 
44% (14). A more recent study from Queensland, Australia showed that 43% of people 
with BCC developed a second BCC within 4.5 years (15).
 KTR who started with SCC mainly developed SCC as subsequent skin cancers and 
recipients who started with BCC mainly developed BCC. This could possibly be 
explained by different lifestyle factors of the patients. The risk of SCC is considered 
to be associated with chronic cumulative sun exposure whereas BCC is more 
associated with intermittent, intense sun exposure (28). Alternatively, a state of 
immune  unresponsiveness may have been induced by the occurrence of the first 
skin cancer with immunologic tolerance to subsequent skin cancers with the same 
antigenic profile as the possible result. 
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 The type of maintenance immunosuppressive therapy was the most important risk 
factor of subsequent SCC. Patients who were immunosuppressed with Aza had an 
almost three times increased risk of subsequent SCC compared to patients who were 
immunosuppressed with CsA. The period of transplantation between 1986 and 1995 
was associated with a decreased risk of SCC in the univariate analyses. This period 
coincided with the start of immunosuppression with CsA. In the multivariate analyses 
this risk disappeared and only the association between immunosuppressive regimen 
and SCC remained. These analyses suggest that the more frequent immunosuppres-
sion with CsA between 1986 and 1995 may explain the less increased risk of SCC in this 
time period. The type of immunosuppression was not significantly associated with 
subsequent SCC in other studies (11,12), but there are several reports that patients 
who are immunosuppressed with Aza have an increased risk of a first SCC compared 
to patients who are immunosuppressed with other drugs (10,29). Aza has been 
recognized to increase photosensitivity of the skin and also enables UVA to directly 
damage DNA (30). These characteristics of Aza may increase the risk of both first and 
subsequent SCC in patients who are chronically using this drug.
 Longer time periods between transplantation and the development of the first 
SCC were associated with an increased risk of subsequent SCC. Apparently, the 
duration of the immunosuppressive therapy influences the development of 
subsequent SCC after the first SCC. The induction period of the first BCC did not 
influence the development of subsequent BCC.
 Male sex has been reported as a risk factor for multiple skin cancers (12,16), but we 
only observed a trend of an increased risk of multiple BCC for male patients. A kidney 
of a living donor compared with a cadaver kidney was associated with an increased 
risk of subsequent BCC but not of subsequent SCC. Additional studies are needed to 
confirm this association. 
 Sun exposure has been reported as an important risk factor for multiple lesions 
(21,31) and Euvrard et al showed that light color of the hair and eyes and fair skin type 
were predictive of multiple SCC (12). In our study we were not able to assess these risk 
factors.
 In conclusion, this study confirmed and consolidate that skin cancer multiplicity, 
in particular of SCC, is very common in KTR. Transplant physicians should be aware of 
this problem and easy accessible reference of KTR to the dermatologist should be 
accomplished. KTR with a first skin cancer should be carefully checked for subsequent 
skin cancers, preferably at dermatology departments with specialized skin cancer care.
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Trends of skin diseases in organ-transplant recipients 
transplanted between 1966 and 2006: a cohort study 
with follow-up between 1994 and 2006
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Skin diseases are frequently observed in organ-transplant recipients. To count the 
registered skin diseases in all 2136 organ transplant recipients who had been 
transplanted in a single centre between 1966 and 2006 and to calculate their relative 
contribution in relation to the number of years after transplantation. All registered 
skin diseases which were entered into a computerized system between 1994 and 
2006 at the Leiden University Medical Centre were counted and their relative 
contributions were calculated. Between 1994 and 2006, 2408 skin diseases were 
registered in 801 of 1768 organ-transplant recipients who were at risk during this 
specific time period. The most commonly recorded diagnoses were skin infections 
(24.0%) followed by benign skin tumours (23.3%) and malignant skin lesions (18.2%). 
The relative contributions of infectious and inflammatory disorders decreased with 
time after transplantation, whereas the contribution of squamous cell carcinomas 
strongly increased with time. This study gives a systematic overview of the high 
burden of skin diseases in organ-transplant recipients. The relative distributions of 
skin diseases importantly changed with time after transplantation, with squamous 
cell carcinoma contributing most to the increasing burden of skin diseases with 




As a consequence of long-term immunosuppressive therapy cutaneous side effects 
are frequently observed in organ-transplant recipients (OTR) 1-7. Common skin lesions 
in OTRs are viral, fungal and bacterial infections 8-10, and benign, premalignant and 
malignant skin tumours 2-4;6. The most prevalent types of skin cancer in OTRs are 
squamous cell carcinomas (SCC) followed by basal cell carcinomas (BCC) 2;3;11-14.
 The prevalence of skin infections is very high and several studies have described 
that 55-97% of OTRs have some type of infection 9;10;15-17. The spectrum of skin infections 
differs according to the post-transplant time period 10. During the first post-transplant 
month infections result mainly from surgical interventions 8. After the first post-trans-
plant month, the nature of infectious skin diseases is more frequently a result of severe 
immunosuppression, manifesting in infections with herpes viruses (herpes simplex 
virus, varicella zoster virus, cytomegalovirus, Epstein-Barr virus), yeasts (Candida) and 
bacteria 10. Six months and more after transplantation the chronic and progressive 
infections start to exert clinically significant effects 8;10, of which infections with human 
papillomaviruses (HPVs) have been most frequently described 8;18;19.
 The highly increased risks of SCCs and BCCs in OTRs have been frequently 
described 2-4;6. The cumulative incidences of these tumours rise with increasing time 
after transplantation. In highly sun-exposed areas such as Australia the cumulative 
incidence has been reported to be 70% after 20 years 2, whereas in more temperate 
climates, for instance the United Kingdom, the Netherlands, Ireland and Norway, 
cumulative incidences between 20 and 40% after 20 years have been reported 3;4;6;20. 
Compared with the large number of studies focusing on the development of skin 
tumours in OTRs, infectious and inflammatory skin diseases have been studied less 
frequently 8-10;15-19. 
 The first aim of this study was to estimate the frequency of registered skin diseases 
diagnosed in a single centre between 1994 and 2006. The second aim was to calculate 




All 2136 patients who had received a first kidney (n = 1910) or a simultaneous pancreas 
and kidney transplantation (n = 226) between March 1966 and December 2006 at the 
skin diseases in organ-transplant recipients
4
74
Leiden University Medical Centre (LUMC) were included in this cohort study. The 
follow-up period of these patients started in 1994, at the time that computerization 
of the registered skin diseases had started, and ended in December 2006. A total of 
347 patients had died and 21 patients were lost to follow-up before 1994, resulting in 
1225 patients who were at risk at the start of the follow-up period in 1994. Including 
the patients who were transplanted between 1994 and 2006, 1768 patients were at 
risk during the 13-year follow-up period.
 Most of these patients were regularly seen at the Department of Nephrology. 
Those with cutaneous problems were also seen at the Department of Dermatology 
and, since 1996, these patients were concentrated in a specialized OTR skin clinic 
located at the Department of Dermatology of the LUMC. 
 At each visit to the skin clinic the entire skin was checked for skin problems. Special 
attention was focused on the possible presence of keratotic skin lesions and skin 
cancers. Only few patients were monitored by dermatologists in hospitals other than 
the LUMC. Cutaneous diagnoses in clinics outside the LUMC were not considered in 
this study.
 The following baseline characteristics were recorded for every OTR: date of birth, 
sex, date of transplantation and date of death or last follow-up. Permission for the 
study was granted by the Medical Ethical Committee of the LUMC.
Data collection
To identify the registered skin diseases we used several computerized LUMC diagnostic 
registration systems. Starting in 1994 the outpatient clinical information was registered 
with a medical registration program (MEDREG), and inpatient clinical information was 
registered in a National Medical Registration database. In 2003 “diagnosis treatment 
combinations” (DBCs) were introduced in The Netherlands for the registration and 
reimbursement of hospital and medical specialist care and the use of MEDREG was 
abandoned. Between 2003 and 2005 multiple diagnoses per patient per year still 
could be introduced into the DBC system. Since 2005, the DBC system was also used 
for reimbursement of costs by the health insurance, limiting the registration of skin 
diagnoses to one per patient per year. Usually the presenting diagnosis was registered 
and, if there were multiple diagnoses, the most severe diagnosis was registered. 
Registration was based on ICD9 and ICD10 codes allowing the registration of 
most dermatological diagnoses. Follow-up data were used for the period between 
1 January 1994 when computerisation had started and 31 December 2006, the 
arbitrary end of this study. The LUMC diagnostic registration system has the advantage 
that it also diagnoses skin diseases without histological confirmation, but the 
chapter 4
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disadvantage that data collection was not always complete. Owing to the DBC 
registration system, registration of skin diagnoses was limited to one diagnosis per 
patient from 2005 onwards. 
 The skin diseases were categorized into two main groups: A, skin diseases other 
than tumours and B, skin tumours. Group A was subdivided into (i) skin infections; (ii) 
inflammatory skin conditions; (iii) vascular skin problems; (iv) wounds and (v) 
remainder. Group B was subdivided into (i) benign skin tumours; (ii) premalignant skin 
tumours and (iii) malignant skin tumours. We arbitrarily categorized verrucae, 
condylomata and mollusca contagiosa as benign skin tumours because of their 
clinical appearance, although they are caused by members of the papillomavirus and 
poxvirus families, respectively. We categorized keratoacanthoma as a pre-malignant 
skin lesion instead of a benign skin lesion, because in the OTR population keratoa-
canthomas are often difficult to distinguish from SCC.
Statistical analyses
The follow-up time for each patient was computed as the number of years between 
the first transplantation and the end of the study. For the end of the study we used 
the date of the patient’s death, the date of the last follow up or the arbitrary end of 
the study on 31 December 2006. The follow-up years were categorized into categories 
of 5 years ranging from 0-4 years up to 35-39 years after transplantation. The numbers 
of patients at risk were calculated for each follow-up category. 
Results
Registered skin diseases between 1994 and 2006
The number of patients with registered skin diseases and the total number of 
registered skin diseases which were entered into the computerized system between 
1994 and 2006 in OTRs who were transplanted after 1966 and still alive in 1994 are 
presented in Table 1. Altogether 2408 skin diseases were registered in 801 (45.3%) of 
1768 patients who were at risk during this 13-year period, corresponding with a mean 
number of 3.0 skin diseases per patient. The greatest number of skin diseases per 
patient in this period was 34. 
 The 2408 registered skin diseases were equally distributed among skin tumours 
(1274) and other skin diseases (1134) (Table 1). The diagnoses of skin tumours tended 
to concentrate in fewer patients (456 patients) than the other skin diseases (591 
patients). Skin diseases other than tumours were diagnosed almost 10 years earlier 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































compared with skin tumours, at a median of 5.2 and 14.8 years after transplantation, 
respectively (Table 1).
 Focusing on the group of skin diseases other than tumours, the most frequently 
registered diagnoses were skin infections (21.3% of the patients at risk), consisting of 
viral, bacterial, parasitic, fungal and yeast infections (Table 1). Viral infections 
(particularly herpes simplex virus and varicella zoster virus) and yeast infections 
(particularly Candida infections) occurred relatively early, at a median of 2.0 and 2.2 
years after transplantation, respectively. The median times to the diagnoses of 
bacterial and fungal infections were considerably longer, namely 6.8 and 6.3 years 
after transplantation, respectively. Of the bacterial infections folliculitis was more 
common during the first years after transplantation, whereas erysipelas was more 
common after longer post-transplant time periods. 
 Inflammatory skin conditions were also regularly observed in OTRs (11.0% of the 
patients at risk), of which dermatitis, acne and drug-related rashes were the most 
frequently registered skin diseases. As a consequence of the immunosuppressive 
therapy, acne vulgaris and drug rashes developed shortly after transplantation, 
whereas rosacea was seen later after approximately 5 years. Vascular skin problems, 
mainly resulting in ulcers and gangrene, had been registered in 138 patients (7.8% of 
the patients at risk) with a total number of 195 diagnoses and a median time after 
transplantation of 6.2 years (Table 1).
 Focusing on the group of registered skin tumours, 44.0% of the tumours were 
benign (19.2% of the patients at risk), 21.6% premalignant (10.4% of the patients at 
risk), and 34.4% were malignant (10.5% of the patients at risk). The median time from 
transplantation to the registration of the benign tumours was 9.9 years. The median 
time from transplantation to the premalignant and malignant tumours was much 
longer, 16.5 and 17.8 years, respectively (Table 1). The most frequently diagnosed 
benign skin lesions were HPV-related warts (verrucae) and the most frequently 
diagnosed premalignant lesions were actinic keratoses (Table 1). HPV-related warts 
occurred earlier, with a median time after transplantation of 8.6 years, compared with 
actinic keratoses (15.2 years). In turn, actinic keratoses preceded the development of 
malignant tumours (Table 1). The number of registered keratoacanthomas was 
remarkably low, which probably reflects the simultaneous occurrence of SCCs in 
patients with keratoacanthomas and the fact that only the clinically most relevant 
diagnosis was registered.  More than half of the malignant skin lesions were SCCs and 
roughly one third were BCCs. Furthermore, BCCs appeared to occur about 3.5 years 
earlier compared with SCCs (Table 1).

























































































































































































































































































































































































































































































































































Registered skin diseases and histological diagnoses in relation to time after 
transplantation
Figure 1 shows the relative contribution of registered skin diseases according to the 
time period after transplantation. In 93 of 1768 patients (5.3%) altogether 157 skin 
diseases had been registered before transplantation. With 784 registered skin diseases, 
the period between 0 to 4 years after transplantation showed the highest absolute 
number. The absolute numbers of registered skin diseases decreased later after trans-
plantation as a consequence of decreasing numbers of patients at risk during the later 
time categories (Figure 1). The percentage of patients with registered skin diseases 
ranged between 22 and 35%, during the different time periods and the mean number 
of skin diseases per patient ranged between 1.8 and 3.1 during these time periods.
chapter 4
Figure 1   Relative distribution of registered skin diseases in patients with 
one or more skin diseases in relation to different time periods after 
 transplantation.

































5-9 year 10-14 year 15-19 year 20-24 year 25-29 year 30-34 year
0-4 year 5-9 year 10-14 year 15-19 year 20-24 year 25-29 year 30-34 year
Number of patients at risk (max-min)
Infection Inammation Circulation Wound Rest Benign tumor Premalignant tumor Malignant
1768 1768-916 916-678 678-493 493-359 359-191 191-91 91-22
Number of patients with registered skin diseases 93 429 201 172 136 103 54 22
Number of skin diseases 137 784 407 371 359 245 169 53
Mean number of skin diseases per patient 1.7 1.8 2.0 2.2 2.6 2.4 3.1 2.4
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 Within the fi rst 4 years after transplantation, infections and infl ammatory conditions 
accounted for > 50% of all registered skin diseases and this contribution substantially 
decreased with time to < 10% at 30 years after transplantation (Figure 1). The relative 
contribution of benign tumours was stable over time and ranged between 20 and 30%. 
This is in contrast to the premalignant and malignant skin lesions, which contributions rose 
from 3 to 20% and from 4 to 45%, respectively, with increasing time after transplantation 
(Figure 1). When the same analyses were performed after stratifi cation for age (patients 
younger or older than 50 years) and sex similar trends were observed (data not shown).
Discussion
This study gives a systematic overview of the high burden of skin diseases in OTR. 
Each year > 10% of the patients were diagnosed with a skin disease and during a 
13-year period, 48% of the patients had developed one or more skin diseases. Many 
patients developed multiple or recurrent skin diseases. 
 The spectrum of skin diseases changed considerably with increasing time after 
transplantation. The first post-transplant years were dominated by skin infections 
such as herpes simplex, herpes zoster and Candida infection, and inflammatory skin 
diseases such as acne and skin rashes. In the later post-transplant years premalignant 
and malignant skin tumours started to prevail at the expense of infections and 
inflammatory diseases. The median time period after transplantation to the diagnoses 
of common warts was 11.1 years, to actinic keratoses 15.2 years, to BCC 15.9 years and 
to SCC 19.5 years. It is well known that due to the use of immunosuppressive drugs 
OTRs are frequently infected by HPV 18;19;25;26. Interestingly, the prevailing benign 
(warts), premalignant (actinic keratoses) and malignant skin tumours (SCC) are all 
known or thought to be associated with  HPV infection 18;19;25;26. 
 This study confirmed earlier publications that skin infections occur early after 
transplantation 9;10;21, and that skin cancers increase exponentially with increasing time 
after transplantation 2;3;6;12;22. Little is known about vascular skin problems after organ 
transplantation. Our study showed that 138 (7.8%) of 1768 OTRs had some type of skin 
condition related to vascular problems. Both arterial and venous vascular complications 
have been described in renal transplant recipients 23;24 and also simultaneous pancreas 
and kidney transplant recipients are at increased risk for vascular problems as a 
consequence of many years of poorly regulated levels of glucose. To estimate the 
cumulative incidence of vascular skin problems in organ transplant recipients, 
however, additional cohort studies will be necessary. 
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 The LUMC diagnostic registration system has the disadvantage that from 2005 
onwards only one diagnosis per patient per year was allowed to be registered and 
that the registration of skin diseases before 2005 was not always inclusive. The 
numbers of skin diseases presented in this study, therefore, are an underestimation of 
the real number and the type of diagnoses may be biased towards more severe 
diagnoses, such as malignant skin tumours. Although most patients who are 
transplanted at our hospital are regularly seen at the Department of Nephrology and 
those with cutaneous problems are also seen at the Department of Dermatology, we 
cannot exclude that some patients were also seen in other dermatology clinics, which 
may have led to an additional underestimation of the total number of registered skin 
disease. Finally, not every patient will consult a dermatologist for every skin disease, in 
particular when these diseases have few medical consequences, which forms an 
additional source of underreporting.
 In conclusion, the frequency of skin diseases in OTR is high, especially if one 
considers that the number of infections in this study probably represents only the tip 
of the iceberg of the real incidence of skin infections in OTR. Therefore, OTRs should 
be regularly checked by trained dermatologists and given a careful skin examination 
so that skin diseases can be treated at an early stage.
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The purpose of this study was to ascertain the risk of non-melanocytic skin cancer 
(NMSC) in simultaneous pancreas kidney transplant recipients (SPKTRs) compared to 
kidney transplant recipients (KTRs) in relation to other potential risk factors of skin 
cancer. In a cohort study, 208 SPKTRs were compared with 1,111 KTRs who were 
transplanted during the same time period. The effects of age, sex, country of origin, 
time period after transplantation, HLA matching, immunosuppressive regimen and 
rejection treatments on the risk of NMSC were investigated in multivariable Cox’s 
proportional hazard models. In SPKTRs the incidence of NMSC increased from 19 to 
36%, respectively 10 and 15 years after transplantation which was significantly higher 
compared with that in KTRs (6 and 10%, respectively). After adjustment for age and 
sex, SPKTRs had a 6.2 (3.0-12.8) increased risk of squamous-cell carcinoma (SCC) 
compared to KTRs. An additional adjustment for maintenance immunosuppression 
decreased the hazard ratio to 3.1 (1.3-7.2) which indicates partial confounding by the 
immunosuppressive regimen. Adjustment for induction and rejection therapy or HLA 
mismatching did not change the hazard ratio significantly. SPKTRs have an increased 





Organ-transplant recipients are at increased risk for post-transplant neoplasms (Hardie 
et al, 1980; Hartevelt et al, 1990). Non-melanocytic skin cancers (NMSCs), especially 
squamous-cell carcinomas (SCC), are the most common malignancies and can cause 
substantial morbidity and even mortality (Hartevelt et al, 1990; Bouwes Bavinck et al, 
1996; Naldi et al, 2000; Jensen et al, 2000; Euvrard et al, 2003; Otley et al, 2005b; Moloney 
et al, 2006).
 Increasing age, male sex, and fair complexion are the most important host-related 
risk factors for skin cancer, and exposure to sunlight, smoking and infection with 
human papillomaviruses are the most important environmental risk factors (De 
Hertog et al, 2001; Kasiske et al, 2004; Bouwes Bavinck and Feltkamp, 2004; Bouwes 
Bavinck et al, 2008). Among organ-transplant recipients, immunosuppressive therapy 
forms an additional important risk factor (Hartevelt et al, 1990; Bouwes Bavinck et al, 
2007). Both the duration and type of immunosuppression may play a role. Azathioprine 
(Aza) has been reported to induce selective UVA photosensitivity, which may result in 
a cascade of reactions in the skin, ranging from the induction of oxidative stress and 
mutagenic DNA lesions to the development of skin cancer (O’Donovan et al, 2005; 
Ulrich and Stockfleth, 2007; Cooke et al, 2007; Montaner et al, 2007). Cyclosporine A 
(CsA) can decrease DNA repair and impair UV-induced apoptosis, which also increases 
the risk of skin cancer (Yarosh et al, 2005). Poor HLA matching has been reported to be 
associated with an increased risk of NMSC (Bouwes Bavinck et al, 1991).
 Among kidney-transplant recipients (KTRs) living in a temperate climate, the 
prevalence of NMSC at 10 years after transplantation varied between 10 and 27% and 
at 20 years between 40 and 60% (Hartevelt et al, 1990; Bordea et al, 2004; Moloney et 
al, 2006). In Australia, the incidence is even higher (Hardie et al, 1980; Bouwes Bavinck 
et al, 1996; Ramsay et al, 2002). Heart-transplant recipients seem to have a higher 
incidence of NMSC compared with KTRs, although this may be a consequence of 
older age at transplantation in this group (Mihalov et al, 1996; Naldi et al, 2000; Fortina 
et al, 2000). Less research has been conducted in patients receiving a liver transplant. 
After a follow-up period of 10 years, an incidence between 13 and 26% has been 
found in Dutch and Spanish liver-transplant recipients, respectively (Haagsma et al, 
2001; Herrero et al, 2005). There are no studies that followed up lung-transplant 
recipients or simultaneous pancreas kidney transplant recipients (SPKTRs) for a longer 
period.
 Since 1986, simultaneous pancreas kidney transplantations (SPKTs) are being 
performed in the Netherlands. At present, more than 200 patients received an SPKT at 
risk of skin cancer in spktr and ktr
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the Leiden University Medical Center (LUMC). The main objective of this study was to 
calculate the cumulative incidence of skin cancer in SPKTRs compared with the 
incidence in KTRs who were transplanted in the same center during the same time 
period.
 We hypothesized that the risk of skin cancer in SPKTRs would be higher compared 
with that in KTRs, because SPKTRs are exposed to a more potent immunosuppressive 
regimen and are not HLA-matched in contrast to KTRs. 
Results
Baseline characteristics of the KTR and SPKTR 
The baseline characteristics of the KTRs and SPKTRs are depicted in Table 1. The majority 
of the patients originated from the Netherlands. In the KTR group, there were 
significantly more patients originating from Mediterranean countries or from countries 
that are associated with a darker skin type (Table 1). Sex distribution did not differ 
significantly between the two groups, but the SPKTRs were on an average 7.4 years 
younger at first transplantation than were the KTRs (P < 0.001). The median follow-up 
time of the SPKTRs was shorter (P = 0.014), because, during the first few years, the 
number of SPKTs was still limited (Table 1). After adjustment for age, sex and immuno-
suppressive therapy, overall survival was significantly shorter for SKPTRs compared 
with KTRs, with an adjusted hazard ratio of 2.1 (1.5-3.1).  
Cumulative incidence of skin cancer in the SPKTR compared with that in the KTR
The baseline characteristics of the KTRs and SPKTRs in relation to the development of 
SCC and basal-cell carcinoma (BCC) as first events are depicted in Table 2, and potential 
risk factors for NMSC, SCC and BCC are presented for KTRs and SPKTRs, separately, in 
Supplementary Figure S1 and Supplementary Tables S1a and S1b. Two of the KTRs had 
developed an SCC and a BCC and four only a BCC before transplantation. These skin 
cancers were not considered in the analyses. None of the SPKTRs had developed an 
SCC or a BCC before transplantation. The time period after transplantation was 
significantly associated with the occurrence of SCC and BCC (P < 0.001), but sex was 
not associated with skin cancer (Table 2). In the Cox’s proportional hazard model, 
increasing age at transplantation was a risk factor for both types of skin cancer 
(Supplementary Tables S1a and S1b).  
 During the follow-up period until June 2007, a total of 109 skin cancers (73 SCCs 
and 36 BCCs) were diagnosed in 26 (12.5%) out of 208 SPKTRs (Table 2). During the 
chapter 5
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same follow-up period, 68 (6.1%) out of 1,111 KTRs developed altogether 223 skin 
cancers (102 SCCs and 121 BCCs). The overall SCC:BCC ratio in the KTR was 0.79. This 
ratio gradually increased with increasing time after transplantation with ratios of 0.67, 
0.55, 0.71, and 1.0 during the first 2, 2-7, 8-12, and 13-17 years after transplantation, 
respectively. The overall SCC:BCC ratio in the SPKTR was 1.1. The ratios were 0, 1.1, and 
1.4 during the periods between 2-7, 8-12, and 13-17 years after transplantation, 
respectively.
 The cumulative incidences of NMSC, SCC and BCC in SPKTRs are compared with 
those in KTRs in Figure 1 and Supplementary Figure S2. 
risk of skin cancer in spktr and ktr
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Table 1   Baseline characteristics of 1111 kidney transplant recipients and 208  
simultaneous pancreas kidney transplant recipients.
KTR* SPKTR* P value












Male: N (%) 690 (62.1) 126 (60.6) P = 0.677
Age at transplant (years)
 Median



































*KTR = kidney transplant recipient, SPKTR = simultaneous pancreas kidney transplant recipient.
** After adjustment for age, sex and immunosuppressive therapy overall survival was significantly shorter for 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Possible risk factors for skin cancer
To identify the possible factors that could explain the increased risk of skin cancer 
among SPKTRs compared with KTRs, we analyzed the influence of age, sex, country of 
origin, HLA matching, maintenance immunosuppressive regimen, induction and 
rejection treatments, and level of immunosuppression on the risk of skin cancer within 
the SPKTRs and KTRs (Supplementary Figure S1 and Supplementary Tables S1a and 
S1b). 
HLA matching and skin cancer 
No HLA matching is carried out in SPKTRs. Therefore, the number of mismatches was 
much higher among the SPKTRs than in KTRs (Table 1). HLA mismatching, however, 
chapter 5
Figure 1   Cumulative incidence of skin cancer in 208 simultaneous pancreas 
kidney transplant recipients (SPKTR) compared to 1111 kidney transplant 
recipients (KTR). The numbers of SPKTR and KTR at risk in relation to 
the years after transplantation are indicated in the Table.
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was not significantly associated with SCC or BCC in either the KTRs or the SPKTRs 
(Table 2, Supplementary Figure S1f and Supplementary Tables S1a and S1b).
Immunosuppressive regimens and skin cancer 
The immunosuppressive regimens differed strongly between SPKTRs and KTRs, and 
changed considerably during the years (Table 3). SPKTRs always received triple 
therapy, whereas this regimen was introduced much later in KTRs (Table 3). 
 In both KTRs and SPKTRs, immunosuppressive regimens were associated with the 
development of SCC but not of BCC (Table 2, Supplementary Figure S1e and 
Supplementary Tables S1a and S1b). For the main analyses, the immunosuppressive 
regimens were categorized into three basic treatment groups: Aza in any combination, 
mycophenolatemofetil (MMF) in any combination, or CsA or tacrolimus (Tac) without 
Aza or MMF. 
 In the KTR group, immunosuppression with MMF compared with that with Aza 
was associated with a significantly decreased risk of SCC (Supplementary Figure S1e, 
SCC). The hazard ratio adjusted for age and sex was 0.15 (0.04-0.59) (Supplementary 
Table S1a). Additional adjustments for the simultaneous use of CsA; for triple versus 
duo therapy or for the number of HLA mismatches did not change this hazard ratio 
significantly. In the KTR group, immunosuppression with CsA was also associated with 
a significantly decreased risk of SCC compared with Aza (Supplementary Figure S1e, 
SCC). The hazard ratio adjusted for age and sex was 0.35 (0.15-0.84) (Supplementary 
Table S1a). 
 In the SPKTR group, immunosuppression with MMF compared with that with Aza 
was also associated with a decreased risk of SCC (Supplementary Figure S1e, SCC). The 
hazard ratio could not be calculated, however, because all SCC cases were immuno-
suppressed with Aza in any combination and none with MMF in any combination 
(Table 2 and Supplementary Table S1b). SPKTRs who had maintenance therapy with 
MMF in any combination seemed to have an increased risk of BCC compared with 
patients who were using maintenance therapy with Aza in any combination, although 
statistical significance was not reached, and this increased risk was not observed in 
KTRs (Supplementary Figure S1e, BCC). As almost all SPKTRs were immunosuppressed 
with CsA, either in combination with prednisolone and Aza or with prednisolone and 
MMF (Table 2), the risk of SCC associated with the use of CsA could not be calculated 
in the SPKTR group.













































































































































































































































































































































































































































































































































































































































































































































































































































































Induction and rejection treatments and  
level of immunosuppression in relation to 
skin cancer 
Among SPKTRs, induction or rejection treatments 
with antithymocyte globulin (ATG) or muromonab 
(OKT3) were not associated with an increased risk of 
NMSC, SCC or BCC (Supplementary Figure S1h-j). 
The hazard ratios adjusted for age, sex and immuno-
suppressive therapy for induction and rejection 
treatments to develop NMSC were 0.91 (0.38-2.2) and 
1.5 (0.42-5.4), respectively. For SCC, the adjusted 
hazard ratios were 0.92 (0.29-3.0) and 1.3 (0.15-10.1), 
respectively, and for BCC they were 0.68 (0.18-2.6) 
and 2.4 (0.49-12.1), respectively. 
 Owing of insufficient numbers of induction 
treatments among KTRs in this subgroup, we could 
only calculate the hazard ratios for rejection 
treatments. The adjusted hazard ratios were 0.75 
(0.42-1.4), 0.63 (0.25-1.6), and 0.83 (0.38-1.8) for NMSC, 
SCC and BCC, respectively. 
 As the biological effects of ATG and/or OKT3 are 
supposed to be similar before and after the trans-
plantation, induction and rejection treatments with 
ATG and/or OKT3 were combined. Treatment with 
ATG and/or OKT3 at any time was not significantly 
associated with the development of NMSC, SCC or 
BCC in this study (Supplementary Figure S1j and 
Supplementary Tables S1a and S1b).
 Triple therapy and treatment with ATG and/or 
OKT3 are the most important factors determining 
the level of immunosuppression. By combining these 
treatment modalities, we estimated a “general” level 
of immunosuppression. Using this estimation, the 
level of immunosuppression was not consistently 
associated with NMSC, SCC or BCC (Supplementary 
Figure S1k and Supplementary Tables S1a and S1b). 
In the SPKTR, we also calculated the median daily 











































































































































































































































































































































































































































































































































































































































































































































































































































































doses of prednisone, Aza, MMF, CsA and Tac, none of which were associated with skin 
cancer (data not shown). 
SPKTRs have an increased risk of SCC compared with KTRs, which can be 
partly explained by confounding by an  immunosuppressive regimen 
Non-stratified Kaplan-Meier analyses and analyses stratified for potentially 
confounding factors are shown in Supplementary Figure S2 and non-adjusted and 
adjusted hazard ratios of developing NMSC, SCC or BCC in SPKTRs compared with 
those in KTRs are presented in Table 4.
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Table 4   Risk of skin cancer in simultaneous pancreas kidney transplant recipients 
compared to kidney transplant recipients with adjustment for potentially 











No adjustment 3.0 (1.9;4.8) 4.2 (2.2;8.1) 2.5 (1.3;4.9)
Age 4.0 (2.4;6.5) 6.3 (3.1;13.0) 3.1 (1.5;6.1)
Sex 3.0 (1.9;4.8) 4.1 (2.1;8.0) 2.5 (1.3;4.9)
Age and sex 4.0 (2.4;6.5) 6.2 (3.0;12.8) 3.1 (1.5;6.2)
Age, sex and country of origin* 3.8 (2.3;6.2) 5.7 (2.8;11.8) 3.0 (1.5;6.0)
Age, sex and HLA mismatching** 3.3 (1.7;6.3) 8.3 (3.4;20.2) 1.7 (0.72;4.0)
Age, sex and maintenance 
immunosuppression***
3.0 (1.7;5.5) 3.1 (1.3;7.2) 3.1 (1.4;6.9)
Age, sex and ATG or OKT3 as induction or 
rejection treatment
3.9 (2.3;6.7) 6.3 (2.9;13.9) 2.9 (1.4;6.2)
Age, sex and level of immunosuppression**** 2.4 (1.0;5.9) 6.5 (1.7;25.3) 1.3 (0.43;4.0)
Age, sex, HLA mismatching and maintenance 
immunosuppression
2.5 (1.2;5.1) 3.8 (1.4;10.2) 1.8 (0.68;4.5)
*Netherlands and neighbor countries; Mediterranean countries; or Suriname, Africa or Asia.
**No; 1-3; or 4-6 HLA A, B and DR mismatches.
***Aza in any combination; MMF in any combination; or CsA or Tac without Aza or MMF,
****Low, moderate, high or very high immunosuppression as explained in the methods.
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 The Kaplan-Meier analyses show an increased risk of SCC in SPKTRs compared 
with that in KTRs in almost all strata (Supplementary Figure S2). Supplementary Figure 
S2d shows that SPKTRs were much younger at transplantation than were KTRs. 
Adjustment for age, therefore, increased the hazard ratio for the association between 
transplanted organ and SCC (Table 4). Supplementary Figure S2f shows that risk of SCC 
was much lower in the group of patients who were immunosuppressed with MMF in 
any combination. Adjustment for maintenance immunosuppression decreased the 
hazard ratio for the association between transplanted organ and SCC, which was 
adjusted for age and sex from 6.2 (3.0-12.8) to 3.1 (1.3-7.2), which suggests a partial 
confounding by maintenance immunosuppression (Table 4). Adjustment for other 
potentially confounding factors did not reduce the hazard ratios for SCC notably 
(Table 4). 
 The risk of BCC in SPKTR compared with that in KTR was reduced after adjustment 
for HLA mismatching and for the level of immunosuppression, and, when all relevant 
potentially confounding factors were introduced into the Cox’s proportional hazard 
model, the increased risk of BCC largely disappeared (Table 4).
Discussion
This study showed, after adjustment for age and sex, a 6.2-fold (95% CI: 3.0-12.8) 
increased risk of SCC in SPKTRs than in KTRs who were transplanted in the same center 
during the same time period. After an additional adjustment for maintenance immuno-
suppression, this risk decreased to 3.1 (1.3-7.2). The risk of BCC was not statistically 
significantly increased in SPKTRs after adjustment for potentially confounding 
factors.
 Maintenance immunosuppressive therapy with MMF in any combination had 
led to a significantly decreased risk of SCC compared with maintenance immuno-
suppressive therapy with Aza. SPKTRs were more often immunosuppressed with Aza 
than were KTRs. Adjustment for this factor, indeed, reduced the risk of SCC in SPKTRs 
compared with that in KTRs, suggesting that the increased risk of SCC in SPKTR can be 
partly explained by confounding by the type of maintenance immunosuppressive 
therapy. There remained, however, a statistically significant three-fold increased risk of 
SCC in SPKTR, for which we looked for other potential explanations.
 Apart from an obligate history of diabetes in the SPKTRs and differences in 
maintenance immunosuppression, other differences discerning SPKTRs from KTRs are 
more frequent induction and rejection therapies, and the absence of HLA matching 
risk of skin cancer in spktr and ktr
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in SPKTRs. Moreover, these factors could potentially explain the increased risk of SCC 
in SPKTRs compared with that in KTRs.
 The incidence of NMSC in patients with type 1 diabetes has not been systematically 
studied (Zendehdel et al, 2003; Swerdlow et al, 2005). Only Zendehdel et al (2003) showed 
a modest, but statistically nonsignificant increase of NMSC, with a standardized incidence 
ratio of 1.9 (0.6-4.3) in patients who had type 1 diabetes mellitus for more than 15 years 
(Zendehdel et al, 2003). In organ-transplant recipients, diabetes was associated with a 
decreased risk of NMSC (Kasiske et al, 2004; Otley et al, 2005a). It is therefore not likely that 
type 1 diabetes may explain the increased risk of SCC among SPKTRs.
 Induction treatments, impending graft rejection, and the subsequent rejection 
therapies were not associated with SCC or BCC in this study, although the follow-up 
periods may still have been too short to detect such an effect. Adjustment for 
induction and rejection treatments did not change the increased risk of SCC in SPKTRs, 
excluding also these factors as major causes for the increased risk of SCC in SPKTRs.
Although HLA matching has been reported to be associated with skin cancer in an 
earlier study (Bouwes Bavinck et al, 1991), we were not able to confirm this association 
in this study. Adjustment for HLA matching did not influence the risk of SCC among 
SPKTRs; hence, poor HLA matching could not explain the increased risk of SCC in 
SPKTRs. The risk of BCC in SPKTRs, compared with that in KTRs, however, decreased 
after adjustment for HLA matching, suggesting that poor HLA matching could partly 
explain the increased risk of BCC in SPKTRs.
 Differences in the number of induction and graft rejection treatments, as well as 
HLA matching, did not provide a good explanation for the increased risk of SCC in 
SPKTRs compared with KTRs. However, other differences between the two groups 
might be responsible for this outcome. Compared with KTRs, in SPKTRs, a second 
transplanted organ is present. Induction of tolerance is an important goal of clinical 
organ transplantation (Kean et al, 2006; Kawai et al, 2008), and may also have undesirable 
side effects, such as an increased risk of skin cancer. We speculate that transplanted 
pancreas may induce tolerance against an additional set of allo-peptides in the HLA 
antigens of the donor. Although we are not aware of any published examples of this 
mechanism in humans who have received a double set of other organs (for example, 
heart and lung), a reduced rejection rate of the transplanted heart has been described 
in rats who received a heart in combination with a lung or spleen (Westra et al, 1991). An 
increased cross-reactive tolerance against SCC-associated antigens in the host could 
then lead to an increased risk of SCC in SPKTRs, which could potentially affect SCC more 
severely than BCC, as SCCs are more antigenic cancers than are BCCs (Muchemwa et al, 
2006). Future studies should point out whether this hypothesis is true.
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 The overall SCC:BCC ratio in this study was 0.79, which is lower than the ratio of 1.6 
in our earlier study (Hartevelt et al, 1990). After the introduction of maintenance 
therapy with MMF instead of Aza, a decreased risk of SCC was observed, while the risk 
of BCC was not decreased or even possibly increased. Therefore, this change in 
maintenance therapy may explain, at least partly, the lower SCC:BCC ratio. The length 
of the follow-up period may form another explanation, as BCCs tend to occur earlier 
after transplantation than SCCs, but after a latent period, the cumulative incidence of 
SCC increases more rapidly than that of BCC.
 The high collinearity of the immunosuppressive regimen, as well as HLA matching 
with the type of organ transplanted and the relatively limited numbers of first events, 
is the most important limitation of this study. The high collinearity could easily result 
in overfitting in the model so that the association between transplanted organ and 
skin cancer could disappear. The limited numbers of first events provided insufficient 
power, limiting the number of reliable stratified analyses.    
 As the risk of developing skin cancers in transplant recipients is highly increased, 
excessive exposure to sunlight should be avoided and use of daily sunscreen should 
be advised. In addition, strict control in an outpatient clinic is important for diagnosing 




All 208 patients who received a SPKT at the LUMC between March 1986 and January 
2006 were included in this cohort study and were compared with all 1,111 KTRs 
transplanted in the LUMC during the same time period.  The study adhered to the 
Declaration of Helsinki Principles and the medical ethical committee of the LUMC had 
approved the study design.
Collection of data
Data recorded for all SPKTRs and KTRs included the country of origin, the dates of the 
transplantations, age at transplantation, sex, and the dates of death or last follow-up visit. 
During the first post-transplant years, all patients with functional grafts were seen in the 
Department of Nephrology, LUMC. Only 88 (6.7%) patients (4 SPKTRs and 84 KTRs) were 
later followed up in other centers in the Netherlands. In total, 11 (0.8%) patients (1 SPKTR 
and 10 KTRs) were lost to follow-up, mainly because they moved to another country. 
risk of skin cancer in spktr and ktr
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 The country of origin was used as a rough estimation of the skin type.  Altogether, 
1,176 patients originated from the Netherlands or countries with a comparable 
distribution of skin type. A total of 61 patients originated from Mediterranean countries 
(1 from France; 2 from Israel; 2 from Iran; 2 from Iraq; 1 from Italy; 20 from Morocco; 
1 from Spain; 1 from Tunisia; 26 from Turkey; and 5 from (former) Yugoslavia) and 
82 from countries with a dark skin type (29 from Africa; 9 from Indonesia; 5 from 
other parts of Asia; and 39 from Suriname or Dutch Antilles).
Patients with skin problems were also seen and followed up at the Department of 
Dermatology, LUMC. Skin biopsies were routinely carried out when skin cancers were 
suspected. Skin cancer data were collected from the computerized oncological 
registry of the LUMC, the database from the department of Pathology, and from the 
national histological database (PALGRA). Follow-up data were collected until June 
2007. 
 Of 1,111 KTRs, 9 recipients (5 with malignant melanoma, 2 with Kaposi’s sarcoma, 
1 with sweat gland carcinoma and 1 with fibrosarcoma) were present, but no SPKTR 
who developed skin cancers other than NMSC after transplantation. These skin 
cancers are not further discussed. 
Immunosuppressive regimens and HLA matching 
Information about the initial and maintenance immunosuppressive therapy of all 
patients was obtained from the Eurotransplant database. Type of induction therapy 
and the number and type of rejection treatments were collected from the flow sheets 
in the medical charts of the department of nephrology. 
 For SPKTRs, the initial and maintenance immunosuppressive therapy between 
1986 and 1995 consisted of prednisolone (P) (7.5-10 mg/day), Aza (50-100 mg/day) and 
CsA (200-300mg/day). Between 1996 and 2001, almost all new patients were treated 
with prednisolone (7.5-10 mg/day), MMF (2,000 mg/day) and CsA (200-300 mg/day). 
Since 2002 the immunosuppressive treatment of all new patients consisted of 
prednisolone (7.5-10 mg/day), MMF (1,000-1,500 mg/day) and Tac (6-10 mg/day). 
In most SPKTRs, maintenance therapy was identical to initial treatment. 
 For KTRs, immunosuppressive treatment initially consisted of duo therapy with 
prednisolone and Aza, but shortly after 1986, all new KTRs were immunosuppressed 
with prednisolone and CsA. After 1996, triple therapy also became the treatment of 
choice among KTRs, whereby, initially, most new KTRs were treated with prednisolone, 
MMF, and CsA, and later, most new KTRs were treated with prednisolone, MMF and 
Tac. The target blood levels for immunosuppressive drugs were the same for the KTR 
group as for the SPKTR group. Of 1,111 KTRs, in 667 (60%) recipients, maintenance 
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therapy was identical to initial therapy. Starting in 1996, in 39 patients, CsA was 
switched to MMF, and in 23 patients, MMF was added to prednisolone and CsA. Details 
of maintenance immunosuppressive regimens, categorized according to three time 
periods of transplantation, for all SPKTRs and KTRs are provided in Table 3. 
 A total of 112 of the 208 SPKTRs received induction therapy to prevent a rejection 
of the graft by administration of OKT3 (24 patients), ATG (63 patients), daclizumab (23 
patients) or basiliximab (2 patients). With the exception of some rare patients, 
induction treatments with ATG and/or OKT3 were not given to KTRs who were 
transplanted in the LUMC. Starting in 2000, however, induction treatment with 
basiliximab became common practice among KTRs.
 SPKTRs and KTRs, in whom acute graft rejections were observed, were almost 
always initially treated with methylprednisolone. When this therapy was not sufficient 
to prevent further rejection, a second and third rejection treatment with ATG and 
once more with methylprednisolone, respectively, was given. In exceptional cases, 
OKT3 was given when a fourth rejection treatment was needed. 
 To estimate the level of immunosuppression, we categorized the patients into 
four groups. Triple therapy instead of duo therapy and therapy with ATG or OKT3 
as induction or rejection therapy were considered as factors increasing the level 
of  immunosuppression. “Low “ level of immunosuppression was defined as duo 
therapy without induction or rejection therapy with ATG or OKT3; “moderate“ level 
of immunosuppression was defined as (a) triple therapy without induction or 
rejection therapy or (b) duo therapy with induction or rejection therapy with ATG or 
OKT3;  “high“ level of immunosuppression was defined as (a) triple therapy with 
induction or rejection therapy with ATG or OKT3, or (b) duo therapy with both 
induction and rejection therapy with ATG or OKT3;  and “very high“ level of immuno-
suppression was defined as triple therapy and both induction and rejection therapy 
with ATG or OKT3.
 The degree of HLA mismatching for HLA-A, HLA-B, and HLA-DR antigens was 
assessed by counting the antigens present in the donor but absent in the recipient.
Statistical analyses
For analyses of SCCs and BCCs together, we used the term NMSC. We used all recipients 
with SCC (with or without BCC) and all recipients with BCC (with or without SCC) to 
calculate the cumulative incidence of SCCs and BCCs (Kaplan-Meier analyses). For all 
other analyses involving SCC and BCC, we used patients with SCCs or BCCs as 
first event to avoid patients with both SCCs and BCCs being used twice in our 
analyses. Performing our analyses on all recipients with SCC (with or without BCC) or 
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on all recipients with BCC (with or without SCC) did not lead to significantly different 
outcomes.
 The initial and maintenance immunosuppressive therapies were categorized into 
three basic treatment groups: duo or triple therapy with Aza in any combination, duo 
or triple therapy with MMF in any combination, and duo therapy without Aza or MMF 
(i.e. a combination of prednisolone with CsA or prednisolone with Tac). If no data were 
available for the maintenance immunosuppressive therapy, the data of the initial im-
munosuppressive therapy were used. For all our analyses with immunosuppressive 
therapy, we used the subcategorization of maintenance therapy because the patients 
were, generally, exposed to this regimen for the most prolonged period of time. 
 Because ATG and OKT3 exert by far the highest immunosuppressive effect, 
induction and rejection treatments were dichotomized into those with and without 
ATG and/or OKT3. Because the biological effects of ATG and OKT3 are supposed to be 
similar before and after the transplantation, exposures to ATG and/or OKT3 as 
induction or rejection treatment were also combined for our analyses.
 Differences between patients with and without skin cancer were analyzed by 
Chi-square (categorical variables) and Student’s T-tests (continuous variables). 
Kaplan-Meier survival analyses were used to estimate the cumulative incidence of 
skin cancer after transplantation. Cox’s proportional hazard analyses were used to 
calculate hazard ratios for the development of skin cancer and to adjust for potentially 
confounding factors. As opening dates for both analyses, we used the date of the first 
transplantation; as closing dates, we used the date of diagnosis of the first SCC or BCC, 
the date of the patient’s death, the date of last follow-up, the date that they were lost 
to follow-up, or, if the patients were still seen in an outpatient clinic, we used the date 
of the end of the study (1 June 2007). The patients were not censored from analyses 
at graft failure. Censoring patients from analyses because of failure of the first graft 
did not lead to significantly different outcomes. We assessed proportionality of 
hazards by plotting Schoenfeld residuals for relevant covariates and by introducing 
interactions of relevant covariates with time in the Cox’s proportional hazard model.
For all statistical analyses we used SPSS version 14.0.1 (SPSS Inc, Chicago, IL).
Analytic strategy to test for confounding
First, potential risk factors for NMSC, SCC and BCC were identified with Kaplan-Meier 
analyses stratified for SPKTR and KTR (Supplementary Figure S1) and in multivariable 
Cox’s proportional hazard models (Supplementary Tables S1a and S1b).  Subsequently, 
possible confounding of the association between transplanted organ and skin cancer 
was tested with Kaplan-Meier analyses stratified for the potential risk factors of interest 
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(Supplementary Figure S2) and in multivariable Cox’s proportional hazard models 
(Table 4). The Cox’s proportional hazard analyses were initially carried out without any 
adjustment and subsequently with adjustments for age and sex. The hazard ratios 
adjusted for age and sex were further adjusted for other potentially confounding 
factors (Table 4). Age and sex, HLA matching and maintenance immunosuppression 
had the most important modulating effect on the association between transplanted 
organ and skin cancer, and these factors were, therefore, included in the final model. 
Maintenance immunosuppression, use of ATG or OKT3, and level of immunosuppres-
sion could not be included in the model together because of collinearity and 
overfitting.
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Figure S1 a-k: Risk factors for skin cancer
 Non-melanocytic skin cancer (NMSC)
 Squamous-cell carcinoma (SCC)





Figure S2 a-k: Risk of skin cancer in SPKTR compared to KTR stratified for 
different factors
 Non-melanocytic skin cancer (NMSC)
 Squamous-cell carcinoma (SCC)
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SPKTRKTR
A)  Proportion of patients with NMSC by time after transplantation categorized by period of transplantation. 
B)  Proportion of patients with NMSC by time after transplantation categorized by sex. 

































D)  Proportion of patients with NMSC by time after transplantation categorized by age. 
E) Proportion of patients with NMSC by time after transplantation categorized by maintenance 
immunosuppressive regimens. 
F)  Proportion of patients with NMSC by time after transplantation categorized by number of mismatches. 
Fig S1 d-f: Risk factors for NMSC in KTR and SPKTR, page 2. 
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G)  Proportion of patients with NMSC by time after transplantation categorized by duo or triple therapy. In 
the SPKTR none of the patients received duo therapy. 
H) Proportion of patients with NMSC by time after transplantation categorized by induction therapy. In de KTR 
none of the patients received induction therapy. 
I) Proportion of patients with NMSC by time after transplantation categorized by number of rejections. 
Fig S1 g-i: Risk factors for NMSC in KTR and SPKTR, page 3. 
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Abbreviations: KTR = kidney transplant recipients, SPKTR = simultaneous pancreas kidney transplant 
recipients, NMSC = non melanoma skin cancer, Aza = azathioprine, MMF = mycofenolatemofetil, CsA = 
cyclosporine, Tac = tacrolimus, ATG = antithymocyteglobulin, OKT3 = muromonab. 
*Level of immunosuppression is calculated as follows: low; none of the three types of immunosuppression 
(triple, induction or rejection therapy) has been given, moderate; one of three types of immunosuppression 
(triple, induction or rejection) has been given, high; two of three types of immunosuppression (triple, 
induction or rejection) has been given, very high; all types of immunosuppression (triple, induction or 
















J)  Proportion of patients with NMSC by time after transplantation categorized by induction or rejection 
therapy with or without ATG or OKT3. 
K) Proportion of patients with NMSC by time after transplantation categorized by level of 
immunosuppression*; low, moderate, high, very high. In the KTR none of the patients reached a very high 
level of immunosuppression. In the SPKTR none of the patients received a low level of immunosuppression. 
Fig S1 j-k: Risk factors for NMSC in KTR and SPKTR, page 4. 
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A)  Proportion of patients with SCC by time after transplantation categorized by period of transplantation. 
B)  Proportion of patients with SCC by time after transplantation categorized by sex. 
C)  Proportion of patients with SCC by time after transplantation categorized by ethnicity. 
















D)  Proportion of patients with SCC by time after transplantation categorized by age. 
E) Proportion of patients with SCC by time after transplantation categorized by maintenance 
immunosuppressive regimens. 
F)  Proportion of patients with SCC by time after transplantation categorized by number of mismatches. 
Fig S1 d-f: Risk factors for SCC in KTR and SPKTR, page 6. 
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G)  Proportion of patients with SCC by time after transplantation categorized by duo or triple therapy. In the 
SPKTR none of the patients received duo therapy. 
H) Proportion of patients with SCC by time after transplantation categorized by induction therapy. In de KTR 
none of the patients received induction therapy. 
I) Proportion of patients with SCC by time after transplantation categorized by number of rejections. 
Fig S1 g-i: Risk factors for SCC in KTR and SPKTR, page 7. 
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Abbreviations: KTR = kidney transplant recipients, SPKTR = simultaneous pancreas kidney transplant 
recipients, SCC = squamous cell carcinoma, Aza = azathioprine, MMF = mycofenolatemofetil, CsA = 
cyclosporine, Tac = tacrolimus, ATG = antithymocyteglobulin, OKT3 = muromonab. 
*Level of immunosuppression is calculated as follows: low; none of the three types of immunosuppression 
(triple, induction or rejection therapy) has been given, moderate; one of three types of immunosuppression 
(triple, induction or rejection) has been given, high; two of three types of immunosuppression (triple, 
induction or rejection) has been given, very high; all types of immunosuppression (triple, induction or 














J)  Proportion of patients with SCC by time after transplantation categorized by induction or rejection 
therapy with or without ATG or OKT3. 
K) Proportion of patients with SCC by time after transplantation categorized by level of immunosuppression*; 
low, moderate, high, very high. In the KTR none of the patients reached a very high level of 
immunosuppression. In the SPKTR none of the patients received a low level of immunosuppression. 
Fig S1 j-k: Risk factors for SCC in KTR and SPKTR, page 8. 
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A)  Proportion of patients with BCC by time after transplantation categorized by period of transplantation. 
B)  Proportion of patients with BCC by time after transplantation categorized by sex. 
C)  Proportion of patients with BCC by time after transplantation categorized by ethnicity. 














D)  Proportion of patients with BCC by time after transplantation categorized by age. 
E) Proportion of patients with BCC by time after transplantation categorized by maintenance 
immunosuppressive regimens. 
F)  Proportion of patients with BCC by time after transplantation categorized by number of mismatches. 
Fig S1 d-f: Risk factors for BCC in KTR and SPKTR, page 10. 
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G)  Proportion of patients with BCC by time after transplantation categorized by duo or triple therapy. In the 
SPKTR none of the patients received duo therapy. 
H) Proportion of patients with BCC by time after transplantation categorized by induction therapy. In de KTR 
none of the patients received induction therapy. 
I) Proportion of patients with BCC by time after transplantation categorized by number of rejections. 
Fig S1 g-i: Risk factors for BCC in KTR and SPKTR, page 11. 
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Abbreviations: KTR = kidney transplant recipients, SPKTR = simultaneous pancreas kidney transplant 
recipients, BCC = basal cell carcinoma, Aza = azathioprine, MMF = mycofenolatemofetil, CsA = 
cyclosporine, Tac = tacrolimus, ATG = antithymocyteglobulin, OKT3 = muromonab. 
*Level of immunosuppression is calculated as follows: low; none of the three types of immunosuppression 
(triple, induction or rejection therapy) has been given, moderate; one of three types of immunosuppression 
(triple, induction or rejection) has been given, high; two of three types of immunosuppression (triple, 
induction or rejection) has been given, very high; all types of immunosuppression (triple, induction or 












J)  Proportion of patients with BCC by time after transplantation categorized by induction or rejection 
therapy with or without ATG or OKT3. 
K) Proportion of patients with BCC by time after transplantation categorized by level of immunosuppression*; 
low, moderate, high, very high. In the KTR none of the patients reached a very high level of 
immunosuppression. In the SPKTR none of the patients received a low level of immunosuppression. 
Fig S1 j-k: Risk factors for BCC in KTR and SPKTR, page 12. 
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Table S1a   Risk factors of skin cancer in kidney transplant recipients adjusted for age 
and sex using Cox proportional hazard analysis.
Risk factors Non melanocytic
skin cancer
Squamous-cell 
carcinoma as first 
event
Basal-cell 












 Up to 50
 50 – 60










Country of origin 
  Netherlands
 Mediterranean 

































Type of maintenance 
immunosuppression* 
 Aza in any combination
 MMF in any combination










Level of immunosuppression 
 Low
 Moderate










*Aza: azathioprine; MMF: mycophenolate mofetil; CsA: cyclosporine; Tac: tacrolimus.
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Table S1b   Risk factors of skin cancer in simultaneous pancreas kidney transplant 




carcinoma as first 
event
Basal-cell 












 Up to 50
 50 – 59










Country of origin 
  Netherlands
 Mediterranean 





























Type of maintenance 
immunosuppression 
 Aza in any combination
 MMF in any combination
 CsA or Tac
1
1.1 (0.42;3.1)








No SPKTR in this 
group
Level of immunosuppression 












*Aza: azathioprine; MMF: mycophenolate mofetil; CsA: cyclosporine; Tac: tacrolimus.

Cutaneous squamous- and basal-cell carcinomas 
are associated with an increased risk of internal 
malignancies in kidney transplant recipients 
Hermina C. Wisgerhof • Ron Wolterbeek • Johan W. de Fijter • Rein Willemze





The aim of this study was to investigate whether the development of cutaneous 
squamous- and basal-cell carcinomas is associated with an increased risk of internal 
malignancies in kidney transplant recipients. 
In a cohort study, all 1869 patients receiving a kidney transplantation between 1966 
and 2006 at the Leiden University Medical Center were followed. All malignancies 
which had developed between 1966 and 2007 were recorded. Time-dependent Cox 
regression analyses were used to study the association between the development of 
skin cancer and internal malignancies.
Among 1869 kidney transplant recipients, 176 (9.4%) developed cutaneous squamous- 
and 142 (7.6%) basal-cell carcinomas. A total of 142 (7.6%) patients developed internal 
malignancies after transplantation. In patients with squamous-cell carcinoma the 
adjusted risk to develop internal malignancies was 3.5 (2.2-5.6) and for basal-cell 
carcinoma patients, this risk was 2.1 (1.2-3.5). Particularly, the risk to develop carcinomas 
of the digestive organs, lungs and male genital organs was increased.
Kidney transplant recipients with squamous- and basal-cell carcinomas have an 




Kidney transplant recipients (KTR) have a significantly increased risk of malignancy 1-5. 
The incidence of malignancies is 2- to 6-fold higher than in the general population 4-7. 
Especially the incidences of non-melanocytic skin cancer (NMSC), comprising 
squamous-cell carcinoma (SCC) and basal-cell carcinoma (BCC), post-transplant 
lymphoma, anogenital dysplasia, thyroid cancer and Kaposi’s sarcoma are increased 
1;4;6;8-12. NMSC are the most common post-transplant malignancies 9 and many KTR 
develop multiple malignancies 13;14.
 In the general population, patients with a cutaneous SCC have a 2-fold increased 
risk of internal malignancies 15-17, but some studies showed no increased risk of internal 
malignancies, or even a slightly decreased risk, after the development of cutaneous 
SCC 18-20.  In the general population, the development of BCC was also associated with 
an increased risk of internal malignancies 15;21;22. The other way round, internal 
malignancies were also associated with an increased risk of cutaneous SCC {Hemminki, 
2003 2422 /id; Brennan, 2005 2420 /id}.
 No previous studies have investigated the association between NMSC and 
internal malignancies in KTR. In this study we investigated the risk of internal 
malignancies after the development of cutaneous SCC or BCC in KTR.
Material and methods
Patients
We performed a cohort study of all 1869 patients who received a first kidney 
transplantation at the LUMC between March 1966 and January 2006. The follow-up of 
the patients ended arbitrarily on 1 June, 2007. The study adhered to the Declaration 
of Helsinki Principles and the medical ethical committee of the LUMC had approved 
the study design.
Collection of data
Data recorded for all KTR included the date of the first transplantation, age at trans-
plantation, sex, and the dates of cancer, death or last follow-up. The main outcomes 
of cancer were the diagnoses of internal malignancies, cutaneous SCC and/or BCC 
and were collected from the computerized oncological registry of the LUMC, the 
database from the department of Pathology and the national histological database 
(PALGA) 25. The medical charts were also hand searched for the diagnosis of cancer. 
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Premalignant lesions and in situ carcinomas were excluded. 
 The diagnoses of internal malignancies were based on the International 
Classification of Diseases 10th Modification Diagnoses Codes (ICD-10). Different from 
the ICD-10 classification we classified lip carcinomas as cutaneous SCC or BCC and not 
as internal malignancies. 
Immunosuppressive regimens
Between 1966 and 1986, the immunosuppressive treatment of KTR in our clinic 
consisted of duo therapy with prednisolone and azathioprine (Aza), but shortly after 
1986 all new KTR were immunosuppressed with prednisolone and cyclosporine A 
(CsA). From the mid 90th occasionally KTR were treated with prednisolone, mycofeno-
latemofetil (MMF) and CsA.
 KTR, in whom acute graft rejections were observed, were generally initially treated 
with methylprednisolone. When this therapy was not sufficient to prevent further 
rejection a second rejection treatment with ATG and a third rejection treatment with 
once more methylprednisolone were given. In exceptional cases OKT3 was given 
when a fourth rejection treatment was needed. With the exception of some rare 
patients, induction treatments with ATG and/or OKT3 were not given to KTR who 
were transplanted in the LUMC between 1966 and 1995. 
Statistical analyses 
We calculated the time on immunosuppression by adding the times between the 
different transplantations and subsequent rejections or until the patient was censored. 
If there was no rejection, we used the time between the transplantation and the end 
of the study or until the patient was censored (development of malignancy, last 
follow-up visit, or death of the patient).
 For statistical analyses we used Chi-square tests for categorical variables and 
Student’s T-tests for continuous variables. Cox proportional hazard analyses were 
used to calculate hazard ratios for the development of internal malignancies, SCC or 
BCC and to adjust for potentially confounding factors. Time-dependent Cox regression 
analyses were used to measure the effect of time-dependent risk factors. As opening 
dates for the analyses we used the date of the first transplantation; as closing dates we 
used the date of diagnosis of cancer, the date of the patient’s death or the date of last 
follow up. Patients were not censored from the analyses at graft failure.
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 KTR who had already cancer before the first kidney transplantation or patients 
who were lost to follow up at the first transplantation were excluded from all analyses. 
P-values below 0.05 were considered significant. All statistical calculations were 
performed using SPSS for Windows version 16 (SPSS Inc, Chicago, IL).
Results
Baseline characteristics of the KTR
Between March 1966 and January 2006, 1906 patients received their first kidney 
transplant in Leiden. Thirty-seven patients had already a malignancy before the trans-
plantation and they were excluded from further analyses. Of the remaining 1869 KTR 
the median age at transplantation was 43.9 years (range 3.8 – 77.5) with a median 
follow up of 9.2 (range 0 -39.9) years. Altogether, 176 (9.4%) had developed cutaneous 
SCC; 142 (7.6%) BCC and 142 (7.6%) internal malignancies, whereas 1529 (81.8%) KTR did 
not develop any type of cancer. A total of 88 patients developed both SCC and BCC. 
Cutaneous SCC and BCC were, by far, the most frequently diagnosed cancers after 
transplantation 13. In a single patient, the maximum number of SCC was 68 and the 
maximum number of BCC was 28. In total, there were more than 1800 SCC and BCC in 
these patients 13. For this study, however, only the first SCC and BCC were considered. 
One hundred forty-two patients developed together 151 internal malignancies, of 
which 112 were carcinomas, 8 leukemias, 22 lymphomas and 2 sarcomas and in 7 
cases the cellular type was undefined.
 In total, 29 SCC and 8 BCC of the lip had been diagnosed in 31 KTR. In 8 of these 
patients, SCC of the lip was the first presentation of SCC and in 7 patients BCC of the 
lip was the first presentation of BCC. 
Risk factors of cancer
To identify possible risk factors for the development of cutaneous SCC, BCC or internal 
malignancies, we analyzed the influence of sex, age at the first transplantation, the 
years of the first transplantation, the maintenance immunosuppressive therapy and 
time on immunosuppression on the risk of SCC, BCC and internal malignancies (Table 1).
 Patients with SCC were significantly more often male and were significantly 
younger at their first transplantation compared with patients without cancer (Table 1). 
Performing Cox proportional hazard analyses, however, older age at transplantation 
appeared to be a risk factor for the development of SCC, because young patients at 
transplantation were much longer in the follow-up than older patients, as we have 





























































































































































































































































































































































































































































































































































































































































































































































































































reported before 13. By contrast, patients with internal 
malignancies were significantly older at their first 
transplantation than patients who did not develop 
cancer and they were older at the time that they 
developed internal malignancies compared with the 
time that patients developed SCC or BCC (Table 1). 
 As could be expected, most patients with cancer 
were transplanted before 1996 and, as a consequence, 
were more often immunosuppressed with Aza and 
had a longer time on immunosuppression than patients 
without cancer (Table 1).
Patients with cutaneous SCC or BCC are at risk 
for subsequent internal malignancies
Table 2 shows the distribution of patients without 
and with SCC or BCC prior to the development of 
internal malignancies. Of the KTR with internal 
malignancies 22.0% had developed a prior SCC, 
whereas in patients without internal malignancies 
only 7.9% had developed SCC. Adjustment for age 
and sex reduced the hazard ratio, suggesting that 
there was partially confounding by these factors 
for the association between SCC and internal 
malignancies (Table 2). Inclusion of the patients 
who developed SCC after internal malignancies or 
additional adjustment for immunosuppressive therapy 
did not influence the hazard ratios, importantly (data 
not shown). 
 To analyze whether patients with SCC were at 
increased risk for a specific type of internal malignancy, 
time-dependent hazard ratios were calculated for 
the different types of internal malignancy, separately. 
The hazard ratio, adjusted for age and sex, for the 32 
carcinomas of the digestive organs was 4.2 (1.8-9.7), 
for the 21 carcinomas of the lower respiratory system 
4.6 (1.5-14.5) and for the 11 carcinomas of the male 
genital organs 7.3 (1.7-32.5). The risks of other types 



























































































































































































































































































































































































































































































































































































































































































































































































































of internal malignancy, for example of the 22 lymphomas or of the 12 carcinomas of 
the female genital organs were not significantly increased after the development of 
SCC (data not shown). The risk of internal malignancy in BCC patients was only 
significantly increased for the 32 carcinomas of the digestive organs, with a hazard 
ratio of 2.8 (1.1-6.9).
Patients with internal malignancies are not at risk for subsequent SCC  
or BCC
Table 3 shows the distribution of patients without and with internal malignancies 
prior to the development of SCC or BCC. Of the KTR with SCC, 6.8% had developed a 
prior internal malignancy and in KTR with BCC 5.6% had developed a prior internal 
malignancy, whereas in patients without SCC 6.1% had developed an internal 
malignancy and in patients without BCC 6.7% had developed an internal malignancy. 
After adjustment for sex and age the hazard ratios of developing SCC or BCC after the 
development of internal malignancies were not statistically significant (Table 3).  
Patients with BCC are at risk for subsequent SCC, and patients with SCC are 
at risk for subsequent BCC
Table 4 shows the distribution of patients without and with BCC prior to the 
development of SCC and the other way round. Of the KTR with SCC 32.8% had 
developed a prior BCC and of the KTR with BCC 42.6% had developed a prior SCC. BCC 
patients were at a highly increased risk to develop SCC and SCC patients were at a 
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Hazard ratio  
(95% CI)
Hazard ratio 
adjusted for age 
and sex (95% CI)
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Table 4   Risk of squamous-cell carcinoma in patients with prior basal -cell  
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and sex (95% CI)



























highly increased risk to develop BCC (Table 4). Inclusion of the patients who developed 
BCC after SCC and patients who developed SCC after BCC or additional adjustment for 
immunosuppressive therapy did not influence the hazard ratios, importantly (data 
not shown).  
Discussion
This study showed a statistically significantly increased risk of internal malignancies in 
KTR with a prior SCC or BCC compared with KTR without skin cancer, which could be 
largely attributed to an increased risk of carcinomas of the digestive organs, lungs and 
male genital organs. The other way round, KTR with a prior internal malignancy did 
not show an increased risk to develop cutaneous SCC or BCC. KTR with a prior SCC had 
an increased risk of BCC and those with a prior BCC an increased risk of SCC.
 The 3.5 and 2.1-fold increased risks of internal malignancies after a prior SCC or 
BCC, respectively, are compatible with the general population, in which a 1.2-2.0-fold 
increased risk of internal malignancies was reported in patients with a history of SCC 
or BCC 15;19;26. In our study in KTR we did not find an increased risk of SCC or BCC after 
the development of internal malignancies, which is in contrast with the general 
population 23.
 An inherited predisposition of cancer, a suboptimal immune response, or lifestyle 
factors (smoking, sun exposure) are all possible explanations for the increased risk of 
internal malignancies in patients with a prior SCC or BCC. For example, the elevated 
rate of lung carcinoma in patients with a prior SCC, with a hazard ratio of almost 5 in 
our study, is suggestive for a role of smoking, which is a well-known risk factor for 
both lung carcinoma and cutaneous SCC 27. However, in the general population, an 
association between SCC and lung cancer was also apparent after adjustment for 
smoking, so that other factors may play a role, as well 15. 
 Our finding that KTR with a prior SCC have a 3 to 4-fold increased risk of carcinoma 
of the digestive organs is in disagreement with the study of Grant and Tuohimaa 18;20 
who showed, in the general population, no increased risk or even a slightly decreased 
risk of colon carcinoma in patients with a prior diagnosis of skin cancer 18;20. They 
hypothesized that the increased solar ultraviolet B radiation, to which patients with 
NMSC are usually exposed prior to the development of skin cancer, results in higher 
vitamin D levels, which are though to protect, among others, against colon carcinoma 
20;28. On the other hand, Chen et al reported a 78% higher risk for colorectal carcinoma 
in patients with NMSC 15. A possible explanation of this apparent different association 
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may be that Chen’s 15 and our study were performed in countries with relatively low 
amounts of summertime sun exposure (north-eastern part of the United States and 
the Netherlands), compared to Tuohimaa et al 20 showing a reduced risk of cancer in 
countries with high level of sun exposure (Australia, Singapore and Spain).
 A possible limitation of our study is that we did not systematically collect data of 
potentially confounding factors, like smoking, sun exposure, skin type, education 
years and body mass index, so that we cannot adjust for these factors. In another 
study, however, it was shown that, adjustment for these factors did not decrease the 
increased risk of internal malignancies in patients with prior SCC or BCC 15.
 This is the first study in KTR showing an increased risk of internal malignancies, in 
particular carcinomas of the digestive organs, lungs and male genital organs after the 
development of cutaneous SCC or BCC. Both nephrologists and dermatologists 
should be aware of the increased risk of internal malignancies in KTR with prior skin 
cancers and should be extra alert when skin cancers start to develop in their 
patients.
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The risk of cancer is not increased in patients
with multiple kidney transplantations 
Hermina C. Wisgerhof • Ron Wolterbeek • Geert W. Haasnoot • Frans H.J. Claas





The aim of this study was to investigate whether the number of transplantations, as a 
marker of the graft rejection status of the patient, is associated with an increased risk 
of malignancies. In a cohort study, 1213 patients, receiving a kidney transplantation 
between 1966 and 1995 at the Leiden University Medical Center, were analyzed. All 
cutaneous squamous cell carcinoma and internal malignancies, which had developed 
between 1966 and 2007, were recorded. The influence of number of transplantations, 
age, sex and time on immunosuppression on the risk of squamous cell carcinoma and 
internal malignancies was investigated by time-dependent multivariate Cox’s 
proportional hazard models. Of the 1213 kidney transplant recipients, 319 received a 
second kidney, 78 a third; 13 of them a fourth and 4 of them a fifth transplantation. 
After adjustment for potentially confounding factors, including age, sex and years on 
immunosuppressive therapy we did not detect an increased risk of cancer in patients 
with multiple transplantations. On the contrary, patients with three or more trans-
plantations had a 1.6-fold decreased risk of squamous cell carcinomas and a 3.6-fold 
decreased risk of internal malignancies. We conclude that kidney transplant recipients 
with three or more transplantations do not have an increased risk of cutaneous 




Kidney transplant recipients have an increased risk of malignancies of which, in the 
Caucasian population, cutaneous squamous cell carcinoma is the most common one 
(1-9). Chronic immunosuppressive therapy is the major risk factor for the development 
of abundant numbers of malignancies in kidney transplant recipients (2,6,10-12) since 
immunosuppression disrupts antitumor immunosurveillance and anti-viral activity. In 
addition, the higher the cumulative level of immunosuppression, the higher the risk 
to develop malignancies (6,13-15).
 A well-known risk factor for graft rejection is circulating human leucocyte antigen 
(HLA)-antibodies, induced by pregnancy, blood infusion or previous transplantations 
(16-20). Other factors negatively influencing the outcome of kidney transplantation 
include young recipient age (young age is associated with a relatively high state of 
immunologic responsiveness to alloantigens), older donors, recipients of African-
American origin, prolonged cold ischemia time, and systemic diseases such as 
diabetes (16-20). There are also studies suggesting that genetic polymorphisms play a 
role in the clinical outcome of transplantation, although evidence is lacking and large 
prospective studies are needed to show clinical applicability (21,22).
 Patients who are rejecting their grafts are treated with high doses of immunosup-
pressive therapy, including treatments with methylprednisolone, anti-thymocyte 
globulin (ATG) and muronomab-CD3 (OKT3) (23,24). One could speculate that these 
high doses of immunosuppressive rejection therapy lead to a low activated immune 
response and an increased risk of malignancies. There is only one study showing that 
rejection treatments are associated with a higher risk of squamous cell carcinomas 
(25). Using high serum creatinine levels at 1 year after transplantation as a measure of 
graft rejection, Bordea et al showed that patients with high serum creatinine levels 
had a higher risk of developing skin cancer (2). They postulated that patients with a 
high serum creatinine level had maintained higher levels of immunosuppression to 
prevent rejection, which may have led to a higher risk of skin cancer (2). Bordea et al, 
however, did not observe an increased incidence of skin cancer in patients receiving 
additional immunosuppression in the form of rejection treatments with ATG and 
OKT3, which is in line with several other studies (2,10,11,26,27).
 The aim of this study was to investigate whether the number of transplantations, 
which we used as a measure of graft loss, is associated with an increased risk of post-
transplant malignancies. 




Characteristics of all patients and dropouts
Between March 1966 and 31 December 1996, 1246 patients received their first kidney 
transplant in Leiden. Twenty-six patients had already cancer before the transplantation 
and 7 patients were lost to follow up immediately after transplantation. These patients 
were excluded from further analyses. Of the remaining 1213 patients, 237 received the 
first transplantation between 1966 and 1975; 454 between 1976 and 1985 and 522 
between 1986 and 1995. In total, 817 patients lost the first graft and 319 of them received 
a second kidney. Altogether, 78 kidney transplant recipients received a third; 13 of them 
a fourth and 4 of them a fifth transplantation. Of all 1213 kidney transplant recipients, 
752 (62.0%) died, with a median time after transplantation to death of 10.2 years. 
Baseline characteristics of kidney transplant recipients with one, two or 
three or more transplantations
The baseline characteristics of kidney transplant recipients with one, two or three or 
more transplantations are depicted in Table 1. Almost 50% of the patients with only 
one transplantation were transplanted before 1986, whereas 75% of the patients with 
two transplantations and almost 90% of the patients with three or more transplanta-
tions were transplanted before 1986 (Table 1). As a result, the follow-up time was 
statistically significantly longer in the patients with three or more transplantations 
compared to the patients with two transplantations, whereas the latter patients were 
followed longer than the patients with only one transplantation (Table 1).
 The sex distribution did not differ statistically significantly between the three 
groups (Table 1). There was, however, a statistically significant association between 
the number of transplantations and the age at the first transplantation: with increasing 
number of transplantations, the age at the first transplantation was decreasing (Table 1). 
During time, the age of the patients at the first transplantation was significantly 
increasing, but this was less obvious for patients with two or three or more transplantations 
(Table 1). 
 Since most of the patients with two or more transplantations were transplanted 
before 1986, they were initially more frequently immunosuppressed with Aza, whereas 
patients with only one transplantation were more frequently immunosuppressed 
with CsA or Tac (Table 1). Despite important differences in follow-up time, the time on 
immunosuppression was not statistically significantly different between the three 
groups with 12.6, 13.1 and 14.4 years on immunosuppression in patients with one, two 
or three or more transplantations, respectively (Table 1).
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Table 1   Baseline characteristics of the kidney-transplant patients with 1, 2 or  





3 or more 
transplantations
Number of patients: N 894 241 78













Follow-up until last rejection (yrs)#
 Median (25% - 75%)
 0 – 1 years: N (%)
 2 – 7 years
 8 – 12 years
 13 – 17 years
 18 – 22 years
 23 or more years






























Age at first transplantation (yrs)
 Median (25% - 75%) 43.4 (32.2 – 52.5) 34.0 (23.9 – 43.3) 25.6 (18.3 – 33.9)
Immunosuppressive therapy:  N (%)
 Aza combination
 MMF combination










Time on immunosuppression (yrs)
 Median (25% - 75%)
 0 – 9 years
 10 – 19 years
 20 or more years












Aza, azathioprine; MMF, mycophenolatemofetil; CsA, cyclosporine A; Tac, tacrolimus 
# Follow-up until last rejection or end of follow-up or death (when there was a functioning graft at the time  
of death).
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Distribution of squamous cell carcinomas and internal malignancies by 
number of transplantations
In total, 301 (24.8%) of the 1213 kidney transplant recipients developed any type of 
malignancy. During the follow up period 169 (13.9%) out of 1213 patients developed 
at least one cutaneous squamous cell carcinoma. Although there were fewer patients 
with three or more transplantations who developed squamous cell carcinomas, if 
they developed a squamous cell carcinoma, this occurred longer after the transplan-
tation, but at a younger age, which probably reflects their younger age at the first 
transplantation (Table 2). Altogether, 120 (9.9%) out of the 1213 kidney transplant 
recipients developed an internal malignancy. Only 2 (2.6%) patients with three or 
more transplantations developed an internal malignancy and only 7 (8.9%) developed 
a cutaneous squamous cell carcinoma, which is much lower compared to patients 
with only 1 or 2 transplantations (Table 2). Kidney transplant recipients with 4 or 5 
transplantations did not develop any malignancies. Details of the 9 patients with 3 
transplantations and malignancies are provided in Table 3.
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Table 2   Distribution of cancer among the kidney-transplant patients with 1, 2 or  





3 or more 
transplantations
Number of patients: N 894 241 78
Number of patients with SCC: N (%) 123 (13.8) 39 (16.2) 7 (8.9)
Age at first SCC (yrs)
 Median (25% - 75%) 54.2 (45.9-60.2) 52.7 (42.7-58.3) 43.1 (32.8-43.9)
Time from first transplantation to 
first SCC (yrs)
 Median (25% - 75%) 11.8 (7.5-17.5) 14.9 (10.9-20.3) 17.7 (13.0-22.5)
Number of patients with internal 
malignancy: N (%) 94 (10.5) 24 (10.0) 2 (2.6)
Age at internal malignancy (yrs)
 Median (25% - 75%) 58.1 (50.4-62.2) 52.3 (39.3-61.9) 35.1 and 58.8
Time from first transplantation to 
internal malignancy (yrs)
 Median (25% - 75%) 9.9 (4.0-15.4) 11.8 (6.9-17.8) 4.0 and 10.8
SCC, squamous cell carcinoma
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Risk factors of squamous cell carcinomas and internal malignancies 
To identify possible risk factors for the development of cutaneous squamous cell 
carcinomas and internal malignancies, we analyzed the influence of time period of 
the first transplantation, sex, the age at the first transplantation, the number of 
 transplantations, the maintenance immunosuppressive therapy and time on immuno-
skin cancer risk after multiple transplantations
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Table 3   Characteristics of the patients with 3 transplantations and malignancies.



































































suppression on the risk of squamous cell carcinomas and internal malignancies (Table 4). 
Patients with squamous cell carcinoma were more frequently transplanted between 
1966 and 1975 and had a longer follow-up time (Table 4). After adjustment for 
follow-up time, they were significantly older at the first transplantation. Similarly, 
patients with internal malignancies were also significantly older at the first 
 transplantation. Both squamous cell carcinoma and internal malignancy patients 
were more frequently immunosuppressed with Aza and had a longer time on 
immuno suppression than patients without cancer (Table 4).
   
The risk of squamous cell carcinomas and internal malignancies by number 
of transplantations
Figure 1A shows the cumulative incidence of squamous cell carcinomas and figure 1D 
of internal malignancies by number of transplantations. The cumulative incidence of 
squamous cell carcinoma was 8%, 22% and 40%, respectively, 10, 20, and 30 years after 
transplantation in patients with only one transplantation, in contrast with 1%, 11%, and 
14% in patients with three or more transplantations. For internal malignancies the 
cumulative incidences were 7%, 15%, and 23% at the same time points, whereas the 
cumulative incidence of internal malignancies only reached 3% for patients with three 
or more transplantations (Figure 1D). Figures 1A and 1D show that three or more 
 transplantations are not associated with an increased risk of squamous cell carcinomas 
and internal malignancies in kidney transplantation recipients. These figures rather 
suggest a decreased risk of these malignancies in patients with three or more 
 transplantations. Patients with 3 and more transplantations were significantly younger 
at their first transplantation than patients with only 1 transplantation. Figures 1B and 1C 
show the cumulative incidence of squamous cell carcinomas and figure 1E and 1F of 
internal malignancies by number of transplantations stratified for patients who were 
younger or older than 40 years at their first transplantation. In the stratified analyses, 
transplant recipients with 3 and more transplantations still have a decreased risk of 
malignancies, but the differences are less significant, indicating confounding by age. 
Table 5 shows the non-adjusted and adjusted time dependent hazard ratios of 
developing cutaneous squamous cell carcinomas and internal malignancies by number 
of transplantations. In the non-adjusted analyses, we found a significantly decreased 
risk of squamous cell carcinomas in patients with three or more transplantations with 
a hazard of 0.36 (0.15-0.89). Adjustment for age raised the hazard ratio to 0.47 (0.19-1.16), 
also suggesting confounding by age. Additional time-dependent adjustment for years 
on immunosuppression raised the hazard further to 0.62 (0.23-1.6), indicating additional 
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Table 4   Risk factors of cancer in the kidney-transplant recipients.





Number of patients: N* 912 169 120















Follow-up until last rejection (yrs)
 Median (25% - 75%)
 0 – 1 year: N (%)
 2 – 7 years
 8 – 12 years
 13 – 17 years
 18 – 22 years



































Age at first transplantation (yrs)
 Median (25% - 75%) 39.6 (28.5 – 50.5) 38.8 (27.8 – 46.7) 45.2 (34.7 – 51.8) SCC: 0.20
NCM: <0.001






























Time on immunosuppression (yrs)
 Median (25% - 75%)
 0 – 9 years
 10 – 19 years















Aza, azathioprine; MMF, mycophenolatemofetil; CsA, cyclosporine A; Tac, tacrolimus 
* Some patients had both internal malignancy and squamous-cell carcinoma. This fact is reflected here by 
overlapping of the numbers of patients in these categories.
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Figure 1   Cumulative incidence of squamous cell carcinoma by number of 
 transplantations (Panel A), and stratified for patients younger than 
40 years (Panel B)... 
A
Number of patients at risk
1 transplantation 894 652 499 304 165 7
2 transplantations 241 202 174 120 76 3

























3 and more TP
B
Number of patients at risk
1 transplantation 375 308 282 207 129 65
2 transplantations 160 160 124 97 67 34
3 and more TP 67 67 67 52 41 20
























3 and more TP
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Figure 1   ...and patients of 40 years and older at transplantation (Panel C). 
Cumulative incidence of internal malignancy by number of 
 transplantations (Panel D),... 
C
Number of patients at risk
1 transplantation 519 344 217 97 36 9
2 transplantations 81 63 50 23 9 1
3 and more TP 11 11 11 4 2 1
























3 and more TP
D
Number of patients at risk
1 transplantation 894 651 517 330 203 106
2 transplantations 241 202 178 130 86 43





































Figure 1   ...and stratified for patients younger than 40 years (Panel E) and patients 
of 40 years and older at transplantation (Panel F). 
E
Number of patients at risk
1 transplantation 375 307 283 221 156 89
2 transplantations 160 137 124 102 76 41
3 and more TP 67 63 56 53 44 22


































Number of patients at risk
1 transplantation 519 344 234 109 47 17
2 transplantations 81 65 54 28 10 2
3 and more TP 11 11 11 4 2 1


































Both in the non-adjusted and adjusted analyses, the risk of internal malignancies was 
substantially decreased in patients with three or more transplantations, but this was 
based on only 2 occurrences of internal malignancies in the 78 patients with three or 
more transplantations. Because of the low power of these analyses, statistical 
significance was not reached and this result should, therefore, be repeated in a larger 
study. 
 Other potentially confounding factors like HLA mismatching and the level of HLA- 
antigen responses did not influence the hazard ratios for the development of cutaneous 
squamous cell carcinoma and internal malignancies, importantly (data not shown).
Discussion
In the present study we rejected the hypothesis that patients with multiple kidney 
transplantations may have an increased risk of squamous cell carcinomas or internal 
malignancies. On the contrary, we found that, after adjustment for age, sex and duration 
of immunosuppressive therapy, patients with three or more kidney  transplantations 
skin cancer risk after multiple transplantations
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Table 5   Risk of squamous cell carcinoma and internal malignancies in kidney 
 transplant recipients with adjustments for potentially confounding factors 
using time dependent Cox proportional hazard analyses.




  1 transplantation
  2 transplantations

















Age, sex and years on immunosuppression
 1 transplantation
 2 transplantations








had a 1.6 fold decreased risk of cutaneous squamous cell carcinomas and a 3.6 fold 
decreased risk of internal malignancies compared with patients receiving only one 
kidney transplant, but these associations did not reach statistical significance. 
 We conclude that high doses of immunosuppressive rejection therapy with ATG 
and/or OKT3, which are used to treat patients who are rejecting their grafts, are not 
associated with an increased risk of malignancies. We hypothesize that graft loss is an 
indication of a high state of immunologic responsiveness to allogeneic HLA molecules 
in patients who are repeatedly experiencing graft losses, which may lead to a more 
effective (cross-reactive) immune response against malignancies, resulting in a 
decreased risk of malignancies. This high state of immunologic responsiveness may 
override the potentially increased cancer risk induced by high doses of immunosup-
pressive therapy for the treatment of graft rejection. This is in line with several other 
studies showing no association between rejection treatments and the risk of 
cutaneous squamous cell carcinomas (2,10,11,26,27). 
 Increasing age (2,11,28) and increasing number of years on immunosuppression 
(2,3,5,11,28-30) are well-known risk factors for malignancies. A higher state of 
immunologic responsiveness to allogeneic HLA molecules has not been identified as 
a protective factor against malignancies. Heterologous immunity is a term used to 
describe the partial immunity (or altered immunopathology) that occurs in response 
to a pathogen if the host has been previously infected or immunized with an unrelated 
pathogen (31). Similarly, T cells induced by viral exposure and specific for a viral 
peptide in the context of self-HLA may cross-react with allogeneic HLA molecules, 
which implies that memory T cells can be present specific for HLA antigens, toward 
which the patient has never been exposed. Recent data show that this type of 
heterologous immunity is very common (32). Thus, the viral infection can cause an 
increased alloreactivity to allogeneic HLA molecules which limits the induction of 
immunologic tolerance to the graft.
 The other side of the coin is that immunologic tolerance to mismatched HLA 
antigens in patients with well-functioning grafts may result in a diminished immune 
response to viruses. We have shown that simultaneous pancreas kidney transplant 
recipients have an increased risk of squamous cell carcinomas compared to kidney 
transplant recipients (10). We speculated that the transplanted pancreas may have 
induced tolerance against an additional set of allo-peptides in the HLA antigens of 
the donor. An increased cross-reactive tolerance against squamous cell carcinomas 
-associated antigens in the host could have lead to an increased risk of squamous cell 
carcinomas in simultaneous pancreas kidney transplant recipients (10). The association 
between the number of graft losses and the risk of cancer may be based on such a 
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mechanism. We speculate that in patients who have lost several transplants, a higher 
state of immunologic responsiveness to allogeneic HLA molecules leads to 
crossreactive T cell responses to malignancy-associated antigens in the host explaining 
the decreased rate of malignancy in the patients with multiple transplantations 
despite earlier exposure to high doses of immunosuppressive therapy for the 
treatment of graft rejection (33). 
 This study was subjected to several methodological challenges. The power of the 
study may have been not large enough to exclude a type-2 error, i.e. there may be a 
positive association between the number of transplantations and the risk of 
malignancies, but the study was too small to pick this up. The consistently negative 
association between the number of transplantations and the risk of malignancies in 
the adjusted and stratified analyses and the statistically significant negative 
associations in the non-adjusted analyses, however, provide strong arguments against 
a possible type-2 error. Furthermore, the patients with 3 and more transplantations 
were significantly younger at their first transplantation than patients with only 1 trans-
plantation and substantial amounts of time were spent off immunosuppression, so 
that confounding by age and time on immunosuppression formed another serious 
problem. It is possible that the observed negative association between the number of 
transplantations and the risk of malignancies can be completely attributed to the 
younger age of the patients with 3 and more transplantations at their first transplan-
tation and the relatively shorter time on immunosuppression, but after adjustment for 
these factors there was still a negative association between these factors and 
malignancies which could be attributed to a higher state of immunologic 
responsiveness or even other possible residual confounding factors that were not 
tested for.
 In summary, this study rejected the hypothesis that patients with multiple kidney 
transplantations may have an increased risk of cutaneous squamous cell carcinomas 
or internal malignancies and gives some support to the hypothesis that a higher state 
of immunologic responsiveness to allogeneic HLA molecules in these patients, as 
measured by a higher risk of graft losses, may protect against malignancies. More 
studies should be performed, however, to confirm this hypothesis.





All patients who received a first kidney transplantation at the Leiden University 
Medical Center (LUMC) between March 1966, when the kidney transplantation 
program started, and 31 December 1995, allowing for sufficient follow-up time to 
develop malignancies, were included in this cohort study. The follow-up of the 
patients ended arbitrarily on 1 June, 2007. The study adhered to the Declaration of 
Helsinki Principles and the medical ethical committee of the LUMC had approved the 
study design.
Collection of data
Data recorded for each patient included gender, dates of birth, death or last follow-up 
and the dates of the first transplantation and, if appropriate, the dates of the first and 
subsequent graft losses and subsequent re-transplantations. 
 We separately analyzed the risk of cutaneous squamous cell carcinomas and 
internal malignancies. Squamous cell carcinoma and internal malignancy data were 
collected from the computerized oncological registry of the LUMC, the database from 
the department op Pathology and the national histological database (PALGA) (10). 
The Eurotransplant database provided information about the HLA types of the 
recipients and donors and the level of panel reactive antibodies (%PRA). The degree 
of HLA mismatching for HLA-A, B, and DR antigens was assessed by counting the 
antigens present in the donor but absent in the recipient.
Immunosuppressive regimens
Between 1966 and 1986, the immunosuppressive treatment of kidney transplant 
recipients in our clinic consisted of duo therapy with prednisolone and azathioprine 
(Aza), but shortly after 1986 all new kidney transplant recipients were immuno-
suppressed with prednisolone and cyclosporine A (CsA). From the mid 90th occasionally 
kidney transplant recipients were treated with prednisolone, mycofenolatemofetil (MMF) 
and CsA.
 Kidney transplant recipients, in whom acute graft rejections were observed, were 
generally initially treated with methylprednisolone. When this therapy was not 
sufficient to prevent further rejection a second rejection treatment with ATG and a 
third rejection treatment with once more methylprednisolone were given. In 
exceptional cases OKT3 was given when a fourth rejection treatment was needed. 
With the exception of some rare patients, induction treatments with ATG and/or OKT3 
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were not given to kidney transplant recipients who were transplanted in the LUMC 
between 1966 and 1995. 
Statistical analysis
The patients were categorized into patients with one, two or three or more transplan-
tations. We calculated the time on immunosuppression by adding the times between 
the different transplantations and subsequent graft losses or until the patient was 
censored. If there was no graft loss, we used the time between the transplantation 
and the end of the study or until the patient was censored (development of 
malignancy, last follow-up visit, or death of the patient).
 For statistical analyses, we used Chi-square tests for categorical variables and 
Student’s T-tests for continuous variables. Kaplan Meier survival analyses were used to 
estimate the cumulative incidence of squamous cell carcinomas and internal 
malignancies stratified by number of transplantation. Time-dependent Cox 
proportional hazard analyses were used to calculate hazard ratios for the development 
of squamous cell carcinomas and internal malignancies, to adjust for potentially 
confounding factors and to measure the effect of the time-dependent risk factors 
(number of transplantations and time on immunosuppression). P-values below 0.05 
were considered statistically significant. As opening dates for the latter analyses we 
used the date of the first transplantation; as closing dates we used the first occurrence 
of the following mile stones: a) date of diagnosis of the first squamous cell carcinomas 
or internal malignancies, b) the date of the last graft loss, c) the date of the patient’s 
death, d) the date of last follow up or e) if the patients were still followed in the 
outpatient clinic, the date of the end of the study (June 1, 2007).  
 Kidney transplant recipients who had already cancer before the first kidney trans-
plantation or patients who were lost to follow up at the first transplantation were 
excluded from all analyses. All statistical calculations were performed using SPSS for 
Windows version 16 (SPSS Inc, Chicago, IL).
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The risk of (skin) cancer and other skin diseases is highly increased in organ transplant 
recipients (OTR) who are kept on immune suppressive drugs to prevent graft rejection 
(Table 1). This thesis dealt with the epidemiologic aspects and risk factors for cancer, 
focused on cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) 
and other skin diseases in this group of patients. The studies presented in Chapter 
2-4 and 6 focused on descriptive epidemiology, to characterize and report both the 
pattern and frequency of cancer and skin diseases in OTR. Chapter 5 and 7 were 
mainly based on analytic epidemiology, where we searched for new risk factors for 
cancer in OTR. Both descriptive and analytic components together contribute to 
increasing our understanding of this problem in OTR and may be of benefit in the 
design of a more rational clinical follow up of these patients.
 In this concluding chapter, the descriptive as well as analytic epidemiological 
aspects of cancer and skin diseases in OTR are discussed in view of new evidence and 
recent findings by others. In addition, suggestions for future research are provided.
Descriptive epidemiology
Cancer
There is abundant evidence that the incidence of cancer is increased in OTR compared 
with the general population 1-9. We confirmed the high burden of non-melanocytic 
skin cancer (NMSC), melanocytic skin cancer and non-cutaneous malignancies (NCM) 
in kidney transplant recipients (KTR) (Chapter 2) and simultaneous pancreas kidney 
transplant recipients (SPKTR) (Chapter 5). Cancers of the oral cavity, stomach, female 
genital organs, kidney, thyroid gland, but also leukemias and lymphomas, occurred 2 
to 10 times more often compared with the general population. For SCC the 
standardized morbidity ratio even was as high as 40 (Chapter 2). Many of the cancers 
that occurred at increased rates were those with a known or suspected infectious 
cause. Rates of stomach carcinomas were more than doubled and H. Pylori is estimated 
to cause over 60% of all stomach cancer 10. Infection with human papillomavirus type 
16 and 18 are causing cervical cancer 11, 12 and may also play a role in the etiology of a 
part of cancers of the oral cavity 13. Lymphomas are related to Epstein - Barr virus 
infection 14, 15. Several studies have suggested a possible causal role of beta- and 
maybe gamma-papillomavirus infections in the pathogenesis of cutaneous SCC, 




may be crucial in protection from these infection related malignancies, these types 
op cancers may develop predominantly in immunocompromised OTR. Therefore, 
prevention and treatment of infections in OTR may reduce the incidence of 
malignancies.
 We also confirmed the findings of previous studies 22-24 that there is a very high risk 
of subsequent NMSC after the first one (Chapter 3) and we found an increased risk of 
SCC in patients with a prior BCC and vice versa (Chapter 6). Furthermore, we have 
shown that OTR with SCC mainly developed new SCC and those with BCC mainly 
developed BCC (Chapter 3). Possibly, this could be explained by genetic predisposition 
or by different lifestyle factors of the patients, since the risk of SCC is considered to be 
associated with chronic sun exposure, whereas BCCs are more associated with 
intermittent, intense sun exposure 25. Another explanation could be of immunologic 
nature. We hypothesize that a state of immune unresponsiveness may have been 
induced by the occurrence of the first skin cancer with immunologic tolerance to 
subsequent skin cancers with the same antigenic profile as the possible result. 
 We have also found an increased risk of NCM in OTR who developed SCC and BCC, 
but not the other way around (Chapter 6). The increased risks of NCM after the 
development of a prior SCC or BCC are in line with findings in the general population 
26-28. An inherited predisposition of cancer, a suboptimal immune response or lifestyle 
factors (smoking, sun exposure) are all possible explanations for the increased risk of 
NCM in patients with a prior SCC or BCC. Future research may provide insights in 
shared mechanisms of immunity against these types of cancer. We did not demonstrate 
an increased risk of SCC or BCC after the development of NCM, which is in contrast to 
findings in the general population 29.   Firstly, this difference may be explained by a 
lack of power due to the smaller population in our study compared with the 760 000 
patients studied by Hemminki et al. Secondly, due to surveillance bias it is difficult to 
prove the association, since patients with NCM have a high probability of death soon 
after the NCM has been diagnosed, which has been shown in Chapter 2. A higher 
mortality rate is not observed in patients with SCC or BCC (Chapter 2). So far, 
cardiovascular diseases are the leading cause of death in OTR (30-50%), followed by 
infection (17-30%), but as a consequence of longer patient survival and older recipient 
age, malignancies have appeared as the third highest cause of mortality (8-18%) 30 and 
some authors believe that it will surpass cardiovascular diseases as the main cause of 
death in the coming years 31. Therefore, it is very important that future research focuses 




Compared with the large number of studies focusing on the development of skin 
cancer in OTR, infectious and inflammatory skin diseases have been studied less 
frequently 16, 19, 32-37. Despite different methods however, all of these studies concluded 
that the prevalence of skin infections is very high with frequencies varying from 
55-97% (Table 1) 33-37. In Chapter 4 we confirmed the high burden of skin diseases, and 
many patients developed multiple or recurrent skin diseases. The spectrum of skin 
diseases changed considerably with increasing time after transplantation and 
confirmed earlier publications that skin infections (e.g. herpes and candida) already 
occur early after transplantation 33, 34, 38, while most skin cancers increase exponentially 
with increasing time after transplantation 9, 39-42. Although little is known about vascular 
skin problems after organ transplantation, there are some studies describing both 
arterial and venous vascular complications in KTR 43, 44. In our cohort a significant 
proportion (8%) of the OTR does have some type of skin condition related to vascular 
diseases (Chapter 4). These data indicate that dermatologic care in OTR should not 




So far, there is no convincing epidemiological evidence for differences in oncogenic 
potential between the specific immunosuppressive agents. Comparison of incidence 
rate by type of immunosuppressive drug is difficult, because the regimen of immuno-
suppressive agents is strongly associated with the time period in which the patient is 
transplanted and the time period of transplantation has a profound effect on the risk 
of cancer. A recent study showed that treatment with azathioprine (Aza) was associated 
with a significant increased risk for SCC 45. On the other hand, a randomized controlled 
trial in which patients were randomly allocated to one of three different treatment 
groups (Aza and prednisolone vs. long-term cyclosporine vs. short-term cyclosporine 
with a switch to Aza) from Australia, suggest that Aza and cyclosporine-based 
regimens are associated with similar overall long-term skin cancer risk after a follow 
up of 20 years, suggesting that the risk may be mediated by the total burden of 
 immunosuppression rather than the agent 46. Our studies provided additional 
evidence that Aza compared with other immunosuppressive drugs may increase the 




increase photosensitivity of the skin and also enables UVA to directly damage DNA 47. 
These characteristics of Aza may increase the risk of both first as well as subsequent 
SCC in patients who are chronically using this drug. Because most modern transplant 
regimens use combinations of mycofenolatemofetil, the calcineurin antagonist 
chapter 8
Table 1   Skin diseases and (skin) cancer with increased risk in OTR based on the  
literature and this thesis.
Generally starting < 1 year  
after transplantation 

















































tacrolimus and mTOR-inhibitors sirolimus and everolimus, future research should 
focus on these novel immunosuppressive agents. There is evidence to suggest that 
sirolimus compared with other immunosuppressive medications may confer a 
decreased risk of skin cancer 48, 49 due to its antiangiogenic effect, resulting in impaired 
tumor development. This is currently studied at our institute in both animal and 
human experimental studies (RESCUE trial).
 Patients who are rejecting their grafts are treated with high doses of immuno-
suppressive therapy, including treatments with methylprednisolone, anti-thymocyte 
globulin (ATG) and muronomab-CD3 (OKT3) 50, 51. One could speculate that these high 
doses of immunosuppressive rejection therapy lead to a state of severe immune 
deficiency and an increased risk of malignancies. However, there is only one study 
showing that rejection treatments are associated with a higher risk of SCC 52. Using 
high serum creatinine levels at 1 year after transplantation as a measure of graft 
rejection, Bordea et al showed that patients with high serum creatinine levels had a 
higher risk of developing skin cancer 53. They postulated that patients with a high 
serum creatinine level had maintained higher levels of immunosuppression to prevent 
rejection, which may have led to a higher risk of skin cancer 53. However, Bordea et al, 
did not observe an increased incidence of skin cancer in patients receiving additional 
immunosuppression in the form of rejection treatments with ATG and OKT3, which is 
in line with several other studies 53-56. We provided additional evidence that rejection 
therapy is not associated with an increased risk of malignancies. First, in Chapter 5 we 
have shown that impending graft rejection, and the subsequent rejection therapies 
were not associated with SCC or BCC. In addition, Chapter 7 showed that an increased 
number of transplantations are associated with a decreased risk of both SCC and NCM. 
Patients with multiple transplantations have rejected previous grafts, and are therefore 
treated with high levels of immunosuppression, including OKT3 and/or ATG to prevent 
final rejection, during short periods. 
 From 1991 until 1993, SPKTR are routinely treated with OKT3 as induction therapy 
and since 1998, SPKTR are routinely treated with high dose of induction therapy with 
ATG or daclizumab or in exceptional cases with basiliximab to prevent later rejection. 
In Chapter 5 we have shown that induction treatments, similarly as rejection 
treatments, are also not associated with cancer. Apparently, the high levels of immu-
nosuppression in induction and rejection treatments with the expected lower 





Shared immunity against organs and tumors
In Chapter 7 we have shown that the rejection rate is associated with a decreased risk 
of cancer. Patients with three and more transplantations had a 1.6 respectively 
3.6-times decreased risk of both NCM and SCC. A mechanism which may explain the 
prevention of malignancies in OTR is heterologous immunity, which is partial immunity 
that can occur in response to an antigen if the host has been previously immunized 
with an unrelated antigen 57. This can be due to bystander activation or cross- reactivity, 
which is a reaction of a T-cell against more than one antigen. For example, some 
human virus-specific T-cells have been shown to recognize antigens in other HLA 
molecules 58. We speculate that in patients with multiple transplantations bystander 
activation or cross-reactivity between donor grafts and malignancy-associated 
antigens result in protection from development of malignancies (Figure 1 A).
 Supporting the hypothesis of cross-reactivity between donor graft and malignancy, 
we have found evidence that the opposite mechanism may also occur by induction 
of cross-reactive tolerance. Besides immunosuppressive therapy and other risk factors 
induction of immunologic tolerance may play a role in the development of 
malignancies in OTR (Chapter 5 en 7).  Immunologic tolerance is a state of immune 
unresponsiveness to specific antigens induced by previous exposure to these antigens. 
Tolerance may result from T cells recognizing their antigen in a tolerizing environment, 
such as in the presence of immunosuppressive drugs, which may cause suppression, 
functional inactivity or apoptosis of the T cells 59. Cross-reactive tolerance against 
antigens derived from donor organs has been demonstrated in animal models. Rats 
who received a heart in combination with a lung or spleen were more tolerant for the 
transplanted heart, since a reduced rejection rate of the transplanted heart was 
observed 60. We have shown that SPKTR have an increased risk of SCC compared with 
KTR (Chapter 5). We speculate that the transplanted pancreas may have induced 
more tolerance against donor antigens presented in patient or donor HLA molecules. 
An increased cross-reactive tolerance against SCC-associated antigens in the host 
could then lead to an increased risk of SCC in SPKTRs (Figure 1 B and C). This could 
potentially affect SCC more severely than BCC, as SCCs are more antigenic cancers 
than are BCCs 61. Similarly, tolerance may develop towards antigenic NCM. Induction 
of tolerance is a major goal in graft transplantation but these data suggest that the 
induction of tolerance could lead to unwanted side effects, such as an increased risk 
of infections and malignancies. Animal studies which should point out whether this 
hypothesis is true should be performed, so that we can learn more about the 




































































A. The T cell is activated after recognition of its specific kidney antigen in a patient or donor HLA molecule, 
and after recognition of its specific tumor antigen in a patient HLA molecule due to cross-reactivity, which 
may result in rejection of both kidney and tumor. Alternatively, another T cell recognizing the tumor antigen 
is  activated due to bystander activation, which may result in rejection of the tumor. B. The T cell does not 
 respond to recognition of its specific kidney antigen in a patient or donor HLA molecule, and neither to its 
 specific tumor antigen in a patient HLA molecule due to cross-reactive tolerance. Alternatively, another T cell 
recognizing the tumor antigen does not respond due to bystander tolerance. C. Similar to B., but the  presence 
of an increased number of donor antigens derived from the additional transplanted organ  increases the 
 likelihood of occurrence of cross-reactive tolerance or bystander tolerance.
TCR: T cell receptor, HLA: human leukocyte antigen
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Guidelines for dermatologists
In Table 2 we summarize clinical predictors for SCC in OTR to distinguish high risk and 
low risk patients for the development of SCC. The risk factors hatched in grey were 
studied in this thesis. The others are known risk factors from literature 18, 39, 53, 62, 63. 
To reduce the tumor burden in OTR, the management of these patients requires an 
interdisciplinary approach including education about photoprotection, revision of 
immunosuppression and adequate dermatological treatments. Prevention of skin 
cancer in OTR will depend on better patient education. Awareness about skin cancer 
risk, and compliance with photoprotective measures, have indeed improved with 
proper dissemination of information to OTR in specialized dermatology clinics 64. 
Therefore, we recommend that all candidates for transplantation should receive oral 
and written information about dermatological complications after transplantation 
and advice on sun-protective clothing and the use of sunscreen to avoid these 
complications. There is a high need for developing guidelines of dermatological care 
for OTR as these patients represent a significant and increasing challenge to 
dermatologists. In Table 3 we provide a schematic proposal for dermatological 
evaluation and aftercare in OTR based on the results of this thesis and the literature 65. 
Early diagnosis through regular and appropriate follow up preferably in specialized 
dermatology clinics for OTR is strongly recommended. We therefore advise to check 
each OTR at least every two years. Since time after transplantation, resulting in more 
years on maintenance immunosuppression, and older age were risk factors for SCC 
(Chapter 2-7) we advise to check patients using immunosuppression for more than 
10 years or being older than 50 years of age once a year. In these non sun damaged 
patients the focus should be on sun protective measures. Independent on age and 
time on immunosuppression, when patients have signs of severe or moderate sun 
damage, we recommend to checking them twice a year. Individual primary actinic 
keratoses (AK) can be treated with cryosurgery or topical application of imiquimod or 
5-fluorouracil. However, this does not prevent the occurrence of new AK, since the 
areas of ‘field cancerisation’, where a discrete area of tissue is at increased risk of 
developing skin cancer, are not cured. Systemic retinoids can be used for chemo-
prevention since there are studies suggesting that these drugs reduce the number 
of preexisting AK and slow down the development of new lesions 66-68. Tolerability of 
the drug, however, is a major factor limiting its use 67. In addition, it seems reasonable 
to consider revision of immunosuppression in patients with AK, both by reduction of 
the immunosuppressive dose 22 or conversion to sirolimus 48, 49, although more studies 
are needed to determine the potentially beneficial effect of these measures. Since we 
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have shown that the first SCC serves as a predictive marker for multifocal tumor 
development (Chapter 3), patients with a previous SCC, but also patients with 
previous BCC or NCM, should be considered as a high risk group and should therefore 
be checked at least 4 times a year (Table 3). All OTR with rapidly growing (and often 
summary and discussion
8
Table 2   Risk factors for squamous cell carcinoma in organ transplant recipients. 
Risk factors studied in this thesis are hatched in grey.
Risk factors No apparent  
risk factor
Protective factors
Chronic sun exposure Donor type (living/
cadaver)
Multiple kidney transplantations
Painful sunburns Rejection therapy Sirolimus versus other 
maintenance immunosuppression
Fitzpatrick skin type I and II Induction therapy Fitzpatrick skin type V and VI






Older age (at transplantation)
Azathioprine versus other maintenance 
immunosuppression
Simultaneous pancreas kidney 
transplantation
Previous diagnosis of SCC/BCC/NCM
Longer time since transplantation /
years on immunosuppression
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painful) lesions should be seen within 1 to 2 weeks. In OTR with suspected or 
biopsy-proven SCC, surgery with histology-controlled margins is the gold-standard 
therapy. In patients with multiple SCC, curettage and electrodessication can be used 
for lesions on the trunk and extremities, since it has been shown that this is an effective 
treatment for SCC in OTR 69, 70 with a low recurrence rate 69. However, strict follow-up 
in specialized dermatology clinics in OTR with multiple SCC is necessary.
Summary and concluding remarks
Descriptive epidemiologic data in this thesis demonstrated and confirmed the major 
morbidity of NCM, NMSC and other skin diseases in OTR. Analytic epidemiologic data 
in this thesis showed that Aza as maintenance immunosuppressive drug is a risk factor 
for first and subsequent SCC. Furthermore, SPKTR have a highly increased risk to 
develop SCC compared with KTR and the rejection rate was shown to be associated 
with a decreased risk of cancer. To our knowledge, these are the first data suggesting 
that besides immunosuppressive therapy, induction of immunologic tolerance may 
play a role in the development of malignancies. 
 Since many malignancies and skin diseases were related to an infectious cause, 
future studies should point out whether prevention and treatment of infections will 
reduce the incidence of both (skin) malignancies and (skin) infections. Considering 
the harmful effects of the classical immunosuppressive agent Aza and the promising 
anticarcinogenic effects of mTOR inhibitors, future studies should aim to study the 
effect of this novel drug class on the risk of malignancies. Since induction of tolerance, 
which is a major goal in graft transplantation, could possibly result in unwanted side 
effects, such as an increased risk of infections and malignancies, it is very important 
that future animal studies should be performed to learn more about the underlying 
mechanisms. 
As far as the mechanisms of tolerance are not clarified yet, the frequent occurrence of 
malignancies in OTR due to immunosuppression should be managed adequately by 
well educated physicians in near future. A proper guideline is needed to provide 
optimal management of OTR, to prevent and reduce morbidity and mortality due to 









visits to dermatology 
outpatient clinic
 Patient characteristics Management
Once in two years No keratotic skin lesions/  
no sun damage
No history of cutaneous 
malignancies
Fitzpatrick skin type V-VI
Less than 10 years after 
transplantation
< 50 years of age
Sun protective measures
Once a year No keratotic skin lesions/  
no sun damage
No history of cutaneous 
malignancies
More than 10 years after 
transplantation OR
> 50 years of age
Sun protective measures
Two times a year Low number (less then 10)  
keratotic skin lesions/ Severe  
to moderate sun damage







Four times a year Patients with more then 10 
keratotic skin lesions/severe  
sun damage




Five and more  
times a year
Multiple previous SCC/BCC See above plus
Complete surgical removal
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De eerste succesvolle orgaantransplantie werd in Boston in 1954 uitgevoerd en betrof 
een transplantatie van een nier tussen twee individuen die genetisch identiek zijn, een 
eeneiige tweeling. Snel daarna werd het door de komst van geneesmiddelen die het 
afweersysteem onderdrukken (immuunsuppressieve geneesmiddelen) ook mogelijk 
organen te transplanteren tussen individuen die genetisch niet identiek zijn. Vanaf 
1966 werden niertransplantaties uitgevoerd in het Leids Universitair Medisch Centrum 
(LUMC). Inmiddels is het ondergaan van een niertransplantatie de beste behandeling 
voor patiënten met ernstig nierfalen. Ondanks het succes van deze therapie zijn er ook 
complicaties. Vanwege het chronisch gebruik van immuun suppressieve genees-
middelen hebben orgaantransplantatiepatiënten een verhoogd risico op het krijgen 
van kanker en infecties. Vooral het risico op niet-gepigmenteerde huidkankers, in het 
bijzonder het plaveiselcelcarcinoom, is sterk verhoogd in deze groep patiënten 
vergeleken met de algemene populatie. Over de exacte incidentie van de verschillende 
typen kanker en (huid)infecties evenals risicofactoren die de kans op deze aandoeningen 
verhogen bestaat nog onduidelijkheid. In dit proefschrift hebben wij getracht meer 
inzicht te verschaffen in de epidemiologische aspecten van kanker en (huid)infecties 
in orgaantransplantatiepatiënten. In het eerste deel (hoofdstuk 2-4 en 6) wordt de 
frequentie van ziekten onderzocht (beschrijvende epidemiologie), terwijl in het 
tweede deel (hoofdstuk 5 en 7) risicofactoren (analytische epidemiologie) voor het 
ontstaan van deze aandoeningen worden bestudeerd.
Hoofdstuk 1 geeft een overzicht van het klinische probleem van (huid)kanker bij 
 orgaantransplantatiepatiënten. De belangrijkste risicofactoren worden besproken, 
zoals immuunsuppressieve geneesmiddelen en ultraviolet licht. Daarnaast wordt 
beschreven wat er bekend is over andere huidaandoeningen dan huidkanker, 
bijvoorbeeld infecties van de huid, in deze patiëntengroep.
Risico op (huid)kanker
In hoofdstuk 2 hebben we onderzocht wat de incidentie is van kanker in patiënten 
die een niertransplantatie hebben ondergaan tussen 1966 en 2006 in het LUMC. Deze 
incidentie hebben we vergeleken met de incidentie in de algehele bevolking. Dertig 
jaar na transplantatie heeft 50% van de patiënten tenminste een vorm van kanker, 
waarbij het plaveiselcelcarcinoom van de huid de meest frequent voorkomende 
kanker is. Kanker van de  keel, slokdarm, maag, nier, schildklier, lymfeklier, beenmerg 
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en vrouwelijk geslachtsorgaan komt 2-10 keer vaker voor bij  niertransplantatiepatiënten 
dan bij de algehele bevolking. Het plaveiselcelcarcinoom van de huid komt zelfs 40 
keer vaker voor. Bij veel van deze typen kanker bestaat een sterke relatie met infecties. 
Omdat het afweersysteem belangrijk is bij de protectie tegen deze infecties, lijkt het 
verklaarbaar dat juist deze typen van kanker veel voorkomen bij transplantatiepatiën-
ten. Veel van de resultaten van deze studie komen overeen met eerder beschreven 
studies. Het verhoogde risico op het ontstaan van schildklierkanker was slechts een 
keer eerder beschreven. Mogelijk speelt ook hier een infectie een rol.
Hoewel het risico op een eerste huidkanker in patiënten met een  orgaantransplantatie 
goed bekend is, is er weinig bekend of transplantatiepatiënten meer dan een 
huidkanker ontwikkelen en hoe snel deze ontstaan nadat de eerste huidkanker zich 
heeft ontwikkeld. In Hoofdstuk 3 hebben we dit apart onderzocht voor twee typen 
huidkanker, het plaveiselcelcarcinoom en het basaalcelcarcinoom. Van de patiënten 
met een niertransplantatie die een plaveiselcelcarcinoom ontwikkelden kreeg 75% 
binnen 5 jaar minimaal een extra plaveiselcelcarcinoom. Dit percentage is veel hoger 
dan bij de algemene populatie waar slechts 20% van de patiënten met een plaveisel-
celcarcinoom een tweede tumor heeft ontwikkeld na 5 jaar. Van de patiënten met 
een basaalcelcarcinoom kreeg 51% tenminste een tweede tumor na 5 jaar, wat wel 
vergelijkbaar is met het percentage dat wordt gezien bij de algemene populatie.  
Risico op andere huidziekten dan huidkanker
In tegenstelling tot het ontstaan van huidkanker bij orgaantransplantatiepatiënten is 
er weinig bekend over andere huidaandoeningen die worden gezien bij orgaantrans-
plantatiepatiënten. In hoofdstuk 4 wordt een overzicht gegeven hoeveel patiënten 
die een nier of een nier en alvleesklier getransplanteerd hebben gekregen tussen 
1966 en 2006 in het LUMC in datzelfde ziekenhuis zijn gezien op de afdeling 
dermatologie tussen 1994 en 2006. In totaal werden er 2408 huidziekten geregistreerd 
in 801 van de 1768 orgaantransplantatiepatiënten. De meest frequent voorkomende 
diagnose was huidinfectie (24%), gevold door benigne huidtumor (23%) en maligne 
huidtumor (18%), waaronder het plaveiselcelcarcinoom en het basaalcelcarcinoom 
valt. Opvallend is dat het spectrum van huidziekten verandert gedurende de tijd na 
transplantatie. De eerste jaren na transplantatie domineren huidinfecties, zoals huid-
afwijkingen ten gevolge van het herpes simplex virus of de schimmel Candida 
Albicans, terwijl langer na transplantatie huidtumoren domineren. Omdat er ook 
patiënten in andere ziekenhuizen door dermatologen zijn gezien of een huisarts 
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hebben geconsulteerd zal het aantal patiënten met huidafwijkingen na het ondergaan 
van een orgaantransplantatie waarschijnlijk nog hoger liggen en beschrijft deze 
studie waarschijnlijk een onderrapportage van de werkelijke frequentie van 
huidziekten in deze groep patiënten. 
Risicofactoren voor huidkanker
Immuunsuppressieve geneesmiddelen 
Een belangrijke risicofactor in de ontwikkeling van huidkanker bij orgaantransplantatie-
patiënten is het gebruik van immuunsuppressieve geneesmiddelen die deze 
patiënten gebruiken om afstoting van het orgaan te voorkomen. Het afweersysteem 
is door langdurig gebruik van deze medicijnen niet meer in staat om kankercellen 
op te ruimen. Er zijn veel verschillende typen immuunsuppressieve geneesmiddelen 
in  orgaantransplantatiepatiënten. Sommige geneesmiddelen, zoals azathioprine, 
hebben niet alleen een immuunsuppressief effect, maar ook een direct effect op 
huidcellen dat tot kanker zou kunnen leiden. In tegenstelling tot dit klassiekere 
 immuunsuppressieve geneesmiddel hebben de nieuwere middelen, zoals sirolimus, 
mogelijk juist een remmende werking op de tumorgroei. In hoofdstuk 3 en 5 worden 
verschillende immuunsuppressieve geneesmiddelen als risicofactor op het krijgen 
van eerste en volgende plaveiselcelcarcinomen van de huid onderzocht. Beide studies 
laten zien dat het geneesmiddel azathioprine vergeleken met andere immuun-
suppressieve geneesmiddelen een hoger risico geeft op het ontwikkelen van 
huidkanker. Het gegeven dat azathioprine de fotosensitiviteit van de huid verhoogt 
en in staat is om in combinatie met ultraviolet A licht directe schade aan het DNA kan 
geven, is mogelijk een verklaring voor het verhoogde risico. 
Naast de bovengenoemde immuunsuppressieve geneesmiddelen, die orgaantrans-
plantatiepatiënten chronisch moeten gebruiken (onderhoudsgeneesmiddelen), is het 
soms nodig om tijdelijk aanvullende geneesmiddelen voor te schrijven, bijvoorbeeld 
als er aanwijzingen zijn dat het orgaan wordt afgestoten ondanks de onderhouds-
geneesmiddelen. Dit noemen we rejectiebehandelingen en betreft kortdurende 
maar hoge doseringen immuunsuppressieve behandelingen met methylprednisolon, 
anti-thymocytglobuline en muronomab. In hoofdstuk 5 hebben wij aangetoond dat 
het geven van rejectiebehandelingen geen extra risico vormt voor het ontwikkelen 
van een plaveiselcelcarcinoom van de huid. Mogelijk komt dat omdat deze middelen 
slechts kortdurend gebruikt worden en speelt het chronisch gebruik van immuun-
suppressieve geneesmiddelen een belangrijkere rol.
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De aanwezigheid van kanker
In Hoofdstuk 6 hebben we onderzocht of orgaantransplantatiepatiënten die kanker 
van de interne organen ontwikkelden een hoger risico hebben op het ontwikkelen 
van huidkanker. Op basis van de resultaten van onze studie blijkt dit niet het geval te 
zijn, terwijl in eerdere studies onder de algehele bevolking wel een hoger risico werd 
gevonden. Mogelijk is de mortaliteit van orgaantransplantatiepatiënten met kanker 
zo hoog dat zij niet meer de kans krijgen om een huidtumor te ontwikkelen. Andersom 
wordt er in deze studie wel een verhoogd risico gevonden voor het ontwikkelen van 
kanker bij orgaantransplantatiepatiënten met huidkanker. Patiënten met een plaveisel-
celcarcinoom van de huid hebben een 3.5 keer verhoogd risico op het ontwikkelen 
van kanker van de interne organen en patiënten met een basaalcelcarcinoom hebben 
een 2.1 keer verhoogd risico op het krijgen van kanker van de interne organen. 
Genetische factoren, bepaalde leefstijlgewoonten of immuunfactoren kunnen deze 
bevinding mogelijk verklaren. 
Aantal en type transplantaties 
Hoofdstuk 7 beschrijft een studie waarin onderzocht is of patiënten die vaker een 
orgaantransplantatie ondergingen een ander risico op kanker hebben dan patiënten 
die slechts een keer een orgaan getransplanteerd kregen. De resultaten laten zien dat 
patiënten die 3 keer of vaker een orgaan getransplanteerd kregen een 1.6 keer 
verlaagd risico hebben op kanker. Voor het plaveiselcelcarcinoom van de huid is dit 
risico zelfs 3.6 keer lager. Het is beschreven dat bepaalde immuuncellen (T-cellen) een 
afweerreactie genereren tegen meer dan een antigeen. Dit wordt crossreactieve 
immuun respons genoemd. Wij speculeren dat patiënten die vaker een orgaan-
transplantatie hebben ondergaan niet alleen een afweerreactie hebben tegen het 
getransplanteerde orgaan met afstoting tot gevolg, maar ook een afweerreactie 
tegen kanker geassocieerde antigenen. Hoewel het exacte mechanisme nog niet 
duidelijk is wordt onze hypothese bijgestaan door resultaten beschreven in hoofdstuk 
5. Als een patiënt een orgaan getransplanteerd krijgt en dit niet als lichaamsvreemd 
wordt gezien spreekt men van tolerantie. Zoals T-cellen een crossreactieve 
immuunrespons tegen meerdere antigenen kunnen vertonen, kan ook crossreactieve 
tolerantie tegen meerdere antigenen optreden. Een voorbeeld van de ontwikkeling 
van tolerantie is de betere functie en overleving van een transplantaat in patiënten 
die voorafgaand aan de transplantatie een bloedtransfusie hebben ontvangen. 
Daarnaast is aangetoond dat er minder afstoting was in ratten die naast een hart ook 
een long of milt getransplanteerd kregen. In hoofdstuk 5 hebben wij aangetoond 
dat patiënten die zowel een nier als een alvleesklier getransplanteerd kregen een 
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6 keer hoger risico hadden op het plaveiselcelcarcinoom dan patiënten die alleen een 
nier getransplanteerd kregen. Na correctie voor immuunsuppressieve geneesmiddelen 
was dat risico nog steeds 3 keer verhoogd. Deze bevinding doet veronderstellen dat 
het verhoogde risico op kanker bij transplantatiepatiënten met een nier en alvleesklier 
mogelijk ten dele toe te schrijven valt aan het ontwikkelen van meer tolerantie door 
de aanwezigheid van twee organen.
Hoofdstuk 8 geeft een samenvatting van de resultaten beschreven in de voorgaande 
hoofdstukken en vervolgens worden de bevindingen bediscussieerd. Op basis van 
onze bevindingen beschreven in dit proefschrift worden adviezen gegeven om de 
zorg van orgaantransplantatiepatiënten te verbeteren in een praktische richtlijn voor 
dermatologen. Omdat veel van de typen (huid)kanker en huidziekten bij transplantatie-
patiënten een relatie hebben met infecties, zou toekomstig onderzoek zich kunnen 
richten op  de mogelijkheden van behandeling en preventie van deze infecties met 
als doel om de incidentie van deze latere aandoeningen te reduceren. Gezien de 
veelbelovende anticarcinogene effecten van sirolimus  zouden toekomstige studies 
erop gericht moeten zijn het effect van deze nieuwe immuunsuppressieve 
geneesmiddelen op het risico van kanker te onderzoeken. Omdat het induceren van 
tolerantie bij orgaantransplantatie een belangrijk doel is, maar mogelijk ongewenste 
bijwerkingen geeft zoals een toegenomen risico op infecties en kanker, is het van 
belang om het mechanisme van tolerantie beter te begrijpen.
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